6.9.3: The Heat-Shock Response - Biology

Heat shock response is a cell’s response to intense heat, including up-regulation of heat shock proteins.


Describe how the bacterial stress response enables bacteria to survive adverse and fluctuating conditions in their immediate surroundings such as increases in temperature

Key Points

  • The bacterial stress response enables bacteria to survive adverse and fluctuating conditions in their immediate surroundings.
  • A bacterial cell can react simultaneously to a wide variety of stresses and the various stress response systems interact with each other by a complex of global regulatory networks.
  • The up-regulation of HSPs during heat shock is generally controlled by a single transcription factor; in eukaryotes this regulation is performed by heat shock factor (HSF), while σ32 is the heat shock sigma factor in Escherichia coli.

Key Terms

  • heat shock response: The cellular response to heat shock.

The bacterial stress response enables bacteria to survive adverse and fluctuating conditions in their immediate surroundings. Various bacterial mechanisms recognize different environmental changes and mount an appropriate response. A bacterial cell can react simultaneously to a wide variety of stresses, and the various stress response systems interact with each other by a complex of global regulatory networks.

In biochemistry, heat shock is the “effect of subjecting a cell to a higher temperature than that of the ideal body temperature of the organism from which the cell line was derived. ”

Heat shock response is the cellular response to heat shock includes the transcriptional up-regulation of genes encoding heat shock proteins (HSPs) as part of the cell’s internal repair mechanism. HSPs are also called ‘stress-proteins’ and respond to heat, cold and oxygen deprivation by activating several cascade pathways. HSPs are also present in cells under perfectly normal conditions. Some HSPs, called ‘chaperones’, ensure that the cell’s proteins are in the right shape and in the right place at the right time. For example, HSPs help new or misfolded proteins to fold into their correct three-dimensional conformations, which is essential for their function. They also shuttle proteins from one compartment to another inside the cell and target old or terminally misfolded proteins to proteases for degradation. Additionally, heat shock proteins are believed to play a role in the presentation of pieces of proteins (or peptides) on the cell surface to help the immune system recognize diseased cells. The up-regulation of HSPs during heat shock is generally controlled by a single transcription factor; in eukaryotes this regulation is performed by heat shock factor (HSF), while σ32 is the heat shock sigma factor in Escherichia coli.

Heat shock protein

Heat shock proteins (HSP) are a family of proteins that are produced by cells in response to exposure to stressful conditions. They were first described in relation to heat shock, [1] but are now known to also be expressed during other stresses including exposure to cold, [2] UV light [3] and during wound healing or tissue remodeling. [4] Many members of this group perform chaperone functions by stabilizing new proteins to ensure correct folding or by helping to refold proteins that were damaged by the cell stress. [5] This increase in expression is transcriptionally regulated. The dramatic upregulation of the heat shock proteins is a key part of the heat shock response and is induced primarily by heat shock factor (HSF). [6] HSPs are found in virtually all living organisms, from bacteria to humans.

Heat-shock proteins are named according to their molecular weight. For example, Hsp60, Hsp70 and Hsp90 (the most widely studied HSPs) refer to families of heat shock proteins on the order of 60, 70 and 90 kilodaltons in size, respectively. [7] The small 8-kilodalton protein ubiquitin, which marks proteins for degradation, also has features of a heat shock protein. [8] A conserved protein binding domain of approximately 80 amino-acid alpha crystallins are known as small heat shock proteins (sHSP). [9]

Cellular Stress Responses: Cell Survival and Cell Death

Cells can respond to stress in various ways ranging from the activation of survival pathways to the initiation of cell death that eventually eliminates damaged cells. Whether cells mount a protective or destructive stress response depends to a large extent on the nature and duration of the stress as well as the cell type. Also, there is often the interplay between these responses that ultimately determines the fate of the stressed cell. The mechanism by which a cell dies (i.e., apoptosis, necrosis, pyroptosis, or autophagic cell death) depends on various exogenous factors as well as the cell's ability to handle the stress to which it is exposed. The implications of cellular stress responses to human physiology and diseases are manifold and will be discussed in this review in the context of some major world health issues such as diabetes, Parkinson's disease, myocardial infarction, and cancer.

1. Overview of Cellular Stress Responses

Cells respond to stress in a variety of ways ranging from activation of pathways that promote survival to eliciting programmed cell death that eliminates damaged cells. The cell’s initial response to a stressful stimulus is geared towards helping the cell to defend against and recover from the insult. However, if the noxious stimulus is unresolved, then cells activate death signaling pathways. The fact that the cell’s survival critically depends on the ability to mount an appropriate response towards environmental or intracellular stress stimuli can explain why this reaction is highly conserved in evolution. For example, antioxidant defence mechanisms against oxidative injury and stress proteins such as heat shock proteins occur in lower organisms as well as the mammals.

There are many different types of stress and the response a cell mounts to deal with these conditions will depend on the type and level of the insult. For example, protective responses such as the heat shock response or the unfolded protein response mediate an increase in chaperone protein activity which enhances the protein folding capacity of the cell, thus counteracting the stress and promoting cell survival. The adaptive capacity of a cell ultimately determines its fate.

Therefore, depending on the level and mode of stress, different defense mechanisms and prosurvival strategies are mounted however, if these are unsuccessful, then the cell death programs are activated to eliminate these damaged cells from the organism. The mechanism by which a cell dies, that is, apoptosis, necrosis, pyroptosis, or autophagic cell death, often depends on its ability to cope with the conditions to which it is exposed. In this review we initially discuss the different forms of cell death that can be activated by adaptive responses because activation of death signaling pathways is the ultimate response to all types of persistent irresolvable stress. In Section 3 we will discuss the many types of stress a cell can encounter and the different responses that are activated to survive adverse conditions. Finally, we will discuss the involvement or contribution of cellular stress responses to disease states.

2. Stress-Induced Cell Death

Cell death has many forms and shapes. Cell death research encompasses not only the study of programmed forms of cell death (both apoptosis and autophagic cell death), necrosis and other modes of cellular demise but also the role these phenomena play in physiological and pathological processes including development, aging, and disease.

The cell death field has attracted much attention in the last two decades, mainly because of its relevance to development, degenerative diseases, and cancer. However, the field of cell death research is by no means new [1]. The concepts of cellular demise and associated terminology have been evolving since the 19th century. The term programmed cell death refers to controlled or regulated forms of death associated with a series of biochemical and morphological changes [2–4]. The realization that some forms of cell death were biologically controlled or programmed has led to exploitation of these processes and has made profound impact in various fields of biology and medicine [5–7].

Nowadays, programmed cell death is synonymous with apoptosis however, based on the original definition it also refers to autophagic cell death [8]. The term apoptosis was first used to describe a particular morphology of cell death [9] common to the vast majority of physiological cell deaths. This morphology includes shrinkage and blebbing of cells, rounding and fragmentation of nuclei with condensation, and margination of chromatin, shrinkage, and phagocytosis of cell fragments without accompanying inflammatory responses (in most cases) [9–11]. The morphology of cells undergoing apoptosis appeared dissimilar and distinct from the morphology associated with necrosis [9, 10]. Necrosis, a term commonly used by pathologists, refers to any deaths associated with the loss of control of ionic balance, uptake of water, swelling, and cellular lysis [12, 13]. This lysis releases many intracellular constituents, attracting immune cells and provoking an inflammatory response.

2.1. Apoptosis

During the 1980s, apoptosis became the focus of attention, primarily because of the relative ease with which it could be distinguished morphologically from other types of cell death. Within a few years apoptosis and delineation of the underlying biochemical and molecular pathways dominated cell death research. The discoveries of the Bcl-2 family of proteins [14–16], death receptors [17], caspases [18], mitochondrial cytochrome c release [19], and a role for the endoplasmic reticulum [20] in apoptosis were just a few major milestones in the history of the field. Today the morphological and biochemical changes associated with apoptosis are largely explained by activation of caspases, and apoptosis has become generally accepted as caspase-dependent programmed cell death [21].

Of all the forms of cell death apoptosis is the best characterized and its highly regulated nature makes it an attractive target for therapeutic intervention. Apoptosis is highly conserved throughout evolution [22, 23] and plays a major physiological role in both embryonic development and aging [22, 24]. Various types of cellular stress stimuli have been shown to trigger apoptosis, including chemotherapeutic agents, irradiation, oxidative stress, and ER stress. Caspases, a family of cysteine proteases, act as common death effector molecules in various forms of apoptosis [25]. Caspases are synthesized as inactive proenzymes, which upon activation cleave various substrates in the cytoplasm or nucleus. This leads to many of the morphologic features of apoptotic cell death, for example, polynucleosomal DNA fragmentation, loss of overall cell shape, and nuclear shrinking [22, 25–27].

During apoptosis caspases are activated by different mechanisms. Stimulation of death receptors of the tumor necrosis factor (TNF) receptor superfamily such as CD95 (APO-1/Fas) or TNF-related apoptosis inducing ligand (TRAIL) receptors by their respective ligands or agonistic antibodies results in receptor aggregation and recruitment of the adaptor molecule Fas-associated death domain (FADD) and procaspase-8 to form the death inducing signaling complex (DISC) [26]. Upon recruitment caspase-8 becomes activated and initiates apoptosis by direct cleavage of downstream effector caspases [26]. The mitochondrial pathway to caspase activation is initiated by the release from the mitochondrial intermembrane space of apoptogenic factors such as cytochrome c, apoptosis inducing factor (AIF), second mitochondria-derived activator of caspase (Smac)/direct IAP binding protein with low pI (DIABLO) or Omi/high-temperature requirement protein A2 (HtrA2) [28]. The release of cytochrome c into the cytosol results in caspase-3 activation through formation of the cytochrome c/Apaf-1/caspase-9-containing apoptosome complex [29]. Smac/DIABLO or Omi/HtrA2 promotes caspase activation through neutralizing the inhibitory effects of Inhibitor of Apoptosis Proteins (IAPs) [30]. Activation of caspases has to be tightly controlled because of the potential detrimental effects on cell survival if they are inappropriately activated. For example, resistance to apoptosis can be caused by aberrant function or expression of IAPs [30]. IAPs present a group of endogenous inhibitors of caspases with eight members in human cells, that is, XIAP, cIAP1, cIAP2, survivin, livin (ML-IAP), NAIP, Bruce (apollon), and ILP-2 [30]. All IAP proteins harbor one or more baculovirus IAP repeat (BIR) domains that mediate their inhibitory interaction with caspases [30]. Among the IAP family proteins, XIAP is the most potent inhibitor of caspases and blocks apoptosis by binding to active caspase-3 and -7 and by interfering with caspase-9 activation [30].

In addition, the ratio of antiapoptotic versus pro-apoptotic Bcl-2 family proteins regulates apoptosis sensitivity. The Bcl-2 proteins comprise both anti-apoptotic family members, for example, Bcl-2, Bcl-XL, and Mcl-1, and pro-apoptotic molecules such as Bax, Bak, and BH3 domain only molecules [31]. According to the direct activation model of Bcl-2 protein activation, BH3-only proteins that function as direct activators (such as Bim and the cleaved form of Bid (tBid)), directly bind to Bax and Bak to stimulate their activation [32]. In this model, BH3-only proteins that act as sensitizers such as Bad promote apoptosis by binding to the prosurvival Bcl-2 proteins [32]. In contrast, the indirect activation model proposes that BH3-only proteins activate Bax and Bak in an indirect manner by binding to the multiple anti-apoptotic Bcl-2 proteins that inhibit Bax and Bak, which in turn leads to the release of Bax and Bak [33, 34]. Moreover, apoptosis sensitivity may be controlled by IAPs, through the regulation of additional signaling cascades, for example, the NF-

B, JNK, TNFR, and the ubiquitin/proteasome pathway [30, 35]. The anti-apoptotic mechanisms regulating cell death have also been implicated in conferring drug resistance to tumor cells.

2.2. Autophagic Cell Death

Autophagy (self-eating) is a multistep process that is characterized by the vesicular sequestration and degradation of long-lived cytoplasmic proteins and organelles, for example, mitochondria [36]. The resulting double-membrane vesicle is termed an autophagosome [36]. The discovery of autophagy-related (atg) genes, first in yeast and subsequently in humans, has greatly enhanced the molecular understanding of the mechanisms that are involved in the control of autophagy [36]. The protein product of the tumor suppressor gene Beclin 1 is the mammalian homolog of Atg6 and forms a multiprotein complex together with Vps34, a class III phosphatidylinositol 3-kinase, UVRAG (UV irradiation resistance-associated tumor suppressor gene), and a myristylated kinase (Vps15, or p150 in humans) [36, 37]. This complex is required for the initiation of the formation of the autophagosome. Once this complex forms, Vps34 becomes activated and catalyzes the generation of phosphatidylinositol-3-phosphate, which is required for vesicle nucleation.

Two major protein conjugation systems exist that are required for autophagosome formation, that is, the Atg12–Atg5 conjugation and Atg8-phosphatidylethanolamine conjugation systems [38]. Mechanistically, both conjugation systems function in a manner that is closely related to ubiquitin conjugation to proteins, with corresponding conjugation-assisting enzymes that resemble the E1 and E2 enzymes in ubiquitin conjugation [38]. In the Atg12–Atg5 conjugation pathway, Atg12 is covalently conjugated to Atg5 with the help of the E1-like enzyme Atg7 and the E2-like enzyme Atg10 [36]. In the other conjugation pathway, phosphatidylethanolamine (PE) is conjugated to LC3, one of the mammalian homologues of Atg8 [36]. This process involves the sequential action of the protease Atg4, the E1-like enzyme Atg7 and the E2-like enzyme Atg3. Subsequently, lipid conjugation results in the conversion of the soluble form of LC3, that is, LC3-I, to the autophagic-vesicle-associated form that is termed LC3-II [39]. Thus, LC3 is soluble under unstressed conditions and undergoes association with peripheral membranes of autophagosomes during the induction of autophagy. Via the fusion with lysosomes, the content of autophagosomes is degraded by the action of acid-dependent enzymes [36].

Autophagy is typically observed in cells that are exposed to a variety of metabolic and therapeutic stresses, including growth factor deprivation, inhibition of the receptor tyrosine kinase/Akt/ mammalian target of rapamycin (mTOR) signaling, shortage of nutrients, ischemia/reperfusion, inhibition of proteasomal degradation, the accumulation of intracellular calcium, and endoplasmic reticulum (ER) stress [40–43]. Reactive oxygen species (ROS) may provide a common link between cellular stress signals and the initiation of autophagy, as ROS accumulation has been reported to result in inactivation of the cysteine protease ATG4, which in turn causes accumulation of the ATG8-phosphoethanolamine precursor that is required for the initiation of autophagosome formation [44]. The functional relationship between autophagy and cell death is complex in the sense that, under most cellular settings, autophagy functions as a stress adaptation that prevents cell death, whereas in some circumstances, it constitutes an alternative route to cell death. This complex interrelationship between autophagy and cell death implies that these responses are somewhat linked at the molecular level. However, the key molecular events that eventually determine whether autophagy is protective or destructive are still poorly understood.

Although it is still controversial whether autophagy is protective or toxic for the cells, accumulating evidence suggests that it has beneficial roles in the heart under both physiological and pathological conditions [45, 46]. Autophagy was shown to mediate turnover of intracellular proteins and organelles in the heart and protect against hemodynamic stress [45]. Consistent with this, rapamycin, which induces autophagy by inhibiting mTOR, can protect myocardium against ischemia/reperfusion injury [47]. In contrast, recent studies also demonstrated that downregulation of the transcription factors, activating transcription factor 5 or 7 (ATF5 or ATF7), using siRNA prevented stress-induced cell death [48, 49], suggesting that the level or timing of autophagy may be critical for deciding the fate of the cells. Autophagic cell death has mainly been shown during development. However, during recent years accumulating evidences suggest that inhibition of apoptosis induces cell death that is either associated with or dependent on autophagy [48–50]. There is evidence of cross-talk between apoptosis and autophagy at the molecular level, particularly with regard to the Bcl-2 family. In addition to its role in inhibiting apoptosis, Bcl-2 has also been shown to inhibit autophagy [51, 52] and autophagic cell death [53]. This effect is mediated through the ability of Bcl-2 to interact with Beclin 1, a key protein in autophagosome formation [52]. In fact, Beclin 1 has been shown to be a novel BH3-only protein and to interact with a number of anti-apoptotic Bcl-2 family members including Bcl-2, Bcl-xL, Bcl-w, and Mcl-1 [54–57].

2.3. Necrosis

Necrosis has been considered as an accidental mode of cell death for many years, implying that within a multicellular organism it is an unregulated process. However, there is now mounting evidence that the execution of necrotic cell death is also regulated by a set of signaling pathways [58–60]. For instance, death domain receptors, for example, TNFR1, and Toll-like receptors have been reported to trigger necrosis, in particular in the presence of caspase inhibitors [58]. In addition, necrotic cell death has been reported in response to cellular stress stimuli, including ischemia or glutamate excitotoxicity in neurons or cancer cells exposed to alkylating DNA damaging agents [61–63]. Morphologically, necrosis is characterized by a gain in cell volume, swelling of organelles and plasma membrane rupture, which results in the loss of intracellular contents. Several signal transduction cascades have been described that are involved in the propagation of necrotic cell death. There is mounting evidence that the serine/threonine kinase RIP1 is one of the key mediators of necrotic cell death, at least in the case of death receptors or Toll-like receptors [64, 65]. Studies in RIP1-deficient leukemia cells revealed that RIP1 is required for death receptor-induced necrosis [66, 67]. Furthermore, RIP1 has been described to be required for lipopolysaccharide-induced cell death of macrophages [68]. In line with a central role of RIP1 in necrotic cell death, small molecule inhibitors of RIP1 kinase were reported to protect against ischaemic brain injury in an in vivo model of necrosis [69–71]. In addition to RIP1, there is very recent evidence that RIP3 is also critical for necrotic cell death [72–74]. To this end, RIP3 was identified in an RNA interference screen to be essential for necrosis in response to TNF

stimulation and during virus infection [72, 73]. RIP3 interacts with RIP1 and regulates RIP1 phosphorylation and the generation of ROS [72–74].

Moreover, ROS and calcium constitute important mediators that are involved in the propagation of the necrotic signal in various forms of necrosis, for example, upon stimulation with TNF or exposure to double-stranded DNA [75, 76]. ROS may be generated intracellularly by mitochondria and glycolysis [75, 77]. While the ER is the main intracellular calcium store, mitochondrial calcium has been described to stimulate oxidative phosphorylation, thereby promoting ROS generation [78]. Both ROS and calcium can cause damage to organelles and macromolecules, which contributes to the loss of cell integrity. In addition calcium-mediated activation of calpain can lead to cleavage and inactivation of caspases [79], whereas the ROS can target the active site of caspases and render them inactive [80]. Many stimuli that drive necrosis can inhibit the apoptotic machinery.

3. Cellular Stress Responses

During tissue homeostasis there is an equilibrium between the net growth rate and the net rate of cell death [22]. Upon exposure to cellular stress this physiological homeostasis is in danger. Depending on the type of cellular stress and its severity, the cell’s response can be manifold. In essence, if the stress stimulus does not go beyond a certain threshold, the cell can cope with it by mounting an appropriate protective cellular response, which ensures the cell’s survival. Conversely, the failure to activate or maintain a protective response, for example, if the stressful agent is too strong, results in activation of stress signaling cascades that eventually fuel into cell death pathways [81, 82].

3.1. The Heat Shock Response

One of the main prosurvival activities of cells, the heat shock response, was originally described as the biochemical response of cells to mild heat stress (i.e., elevations in temperature of

C above normal) [83, 84]. It has since been recognized that many stimuli can activate this response, including oxidative stress and heavy metals. One of the main cellular consequences of these stresses is protein damage leading to the aggregation of unfolded proteins. In order to counteract this, cells increase the expression of chaperone proteins that help in the refolding of misfolded proteins and alleviate protein aggregation. This confers a transient protection, leading to a state that is known as thermotolerance, whereby cells become more resistant to various toxic insults, including otherwise lethal temperature elevations, oxidative stress, various anticancer drugs, and trophic factor withdrawal [85–88].

During initiation of the heat shock response general protein transcription and translation is halted, presumably to alleviate the burden of misfolded proteins in the cell. However, transcription factors that enhance expression of a specific subset of protective genes are selectively activated under these conditions these are the heat shock factors (HSFs) [89]. Vertebrate cells have three different HSFs: HSF1 is essential for the heat shock response and is also required for developmental processes, HSF2 and HSF4 are important for differentiation and development, while HSF3 is only found in avian cells and is probably redundant with HSF1 [90, 91]. Cells derived from mice lacking HSF1 are sensitive to stress and are unable to develop thermotolerance or induce heat responsive genes upon heat shock [92–94], which has confirmed that HSF1 in particular is responsible for the heat shock response. More recent work has shown that HSF2 can modulate HSF1-mediated expression of heat-responsive genes [95], suggesting that HSF2 also participates in transcriptional regulation of the heat shock response.

Inactive HSF1 is maintained in a monomeric form in the cytoplasm through interaction with Hsp90 and cochaperones [96, 97] (Figure 1). When the cell is exposed to stressful conditions, there is accumulation of unfolded proteins which compete with HSF1 for Hsp90 binding. Thus, HSF1 is released from the complex stimulating its transition from a monomer to a homotrimer that can translocate to the nucleus and bind to DNA (Figure 1). HSFs bind to upstream sequences (heat shock elements) in the promoters of target genes, leading to the expression of heat shock proteins (Hsps).

Induction of heat shock proteins inhibits apoptosis and promotes cell survival. Exposure of cells to elevated temperatures, oxidative stress, and heavy metals causes accumulation of unfolded proteins, which through activation of HSF1 leads to induction of Hsp27 and Hsp70. These Hsps inhibit apoptosis and promote survival.

Hsps are a set of evolutionary conserved proteins that are grouped into subfamilies with molecular weights of approximately 110, 90, 70, 60, 40, and 15–30 kDa [85, 98]. Some of these, for example, Hsp90, are constitutively expressed and act intracellularly as molecular chaperones, preventing premature folding of nascent polypeptides [99]. Others, particularly Hsp27 and Hsp70, are usually expressed at low basal levels and increase in response to environmental and physiological stressors, and as such they are termed inducible Hsps and are part of the heat shock response [85]. Hsp27 belongs to a subfamily of stress proteins, the small Hsps, which are detectable in virtually all organisms. Hsp27 is also regulated by phosphorylation and dynamic association/dissociation into multimers ranging from dimers to large oligomers [100]. Hsp70 is the inducible member of the 70 kDa family of Hsps. Both Hsp27 and Hsp70 have been shown to protect cells against the induction of cell death by a variety of stresses and by different modes of cell death, including apoptosis [86, 101] and necrosis [102–104]. They achieve these effects directly, through inhibition of cell death pathways, and indirectly, through general prosurvival activities. For example, in their capacity as molecular chaperones, inducible Hsps bind to and aid the refolding of unfolded proteins, thereby preventing protein aggregation [105]. Hsp27 can interact with actin and is thus important for maintaining the integrity of the cytoskeleton which may play a role in promoting survival [106].

Apart from these indirect mechanisms, Hsp27 and Hsp70 can directly inhibit apoptosis by modulating both the intrinsic and the extrinsic apoptosis pathways and by interfering with caspase activation at several different levels [107–109]. Both Hsp27 and Hsp70 have been reported to directly block release of pro-apoptotic factors, including cytochrome c, from the mitochondria [110–112]. In the cytosol, these Hsps can block apoptosome formation and activation of downstream caspases through their ability to bind to cytochrome c and procaspase-3 (in the case of Hsp27) [107, 108] and procaspases -3, -7 and Apaf-1 (in the case of Hsp70) [101, 113–115]. Hsp70 can also interact with and inhibit apoptosis-inducing factor (AIF) thus inhibiting apoptotic nuclear changes [116, 117]. Hsps can also modulate the death receptor pathway. Hsp27 is reported to inhibit DAXX, an adaptor protein that links the Fas death receptor and the ER stress sensor IRE1 to ASK-1 and downstream JNK pro-apoptotic signaling [118]. Hsp70 also inhibits JNK activity [119–121], although this is not observed in all systems [101]. Hsp27 and 70 can also interact with other proteins that regulate cell survival. For example, Hsp27 can interact with the prosurvival Ser/Thr kinase Akt which is suggested to be important for sustained Akt activity [122–124]. Hsp70 can exist in complex with cochaperones, including DnaJ/Hsp40 and BAG-1 which affect its ability to modulate apoptosis [125, 126]. Overall, Hsps can be activated or induced by a number of stresses and they act to protect the cell by influencing a variety of cellular processes which determine cellular fate. Hsps are, in general, prosurvival and anti-apoptotic molecules.

3.2. The Unfolded Protein Response (UPR)

Secretory and membrane proteins undergo posttranslational processing, including glycosylation, disulfide bond formation, correct folding, and oligomerization, in the ER. In order to effectively produce and secrete mature proteins, cellular mechanisms for monitoring the ER environment are essential. Exposure of cells to conditions such as glucose starvation, inhibition of protein glycosylation, disturbance of Ca 2+ homeostasis and oxygen deprivation causes accumulation of unfolded proteins in the ER (ER stress) and results in the activation of a well orchestrated set of pathways during a phenomenon known as the unfolded protein response (UPR) [127, 128] (Figure 2). The UPR is generally transmitted through activation of ER resident proteins, most notably inositol-requiring protein-1 (IRE1), protein kinase RNA (PKR)-like ER kinase (PERK), and activating transcription factor 6 (ATF6). In some cells/tissues, additional ATF6-like bZip type transcription factors such as OASIS, CREB-H, Tisp40, and Luman also transmit the UPR signaling [129–132]. The UPR target genes include molecular chaperones in the ER, folding catalysts, subunits of translocation machinery (Sec61 complex), ER-associated degradation (ERAD) molecules and anti-oxidant genes [127].

ER stress and the unfolded protein response. Stress to the ER stimulates the activation of the three endoplasmic reticulum (ER) stress receptors, PKR-like ER kinase (PERK), activating transcription factor 6 (ATF6) and inositol-requiring enzyme 1 (Ire1) that are involved in the unfolded protein response (UPR). PERK phosphorylates eukaryotic initiation factor 2 (eIF2α) which inhibits general protein translation, allowing eIF2α-independent translation of ATF4, which activates transcription of chaperones such as GRP78. ATF6 undergoes specific proteolysis in the Golgi apparatus which leads to activation. One of the ATF6 target genes is XBP1. IRE1 catalyzes the alternative splicing of XBP1 mRNA leading to expression of the active XBP1 transcription factor. Together the three arms of the UPR block protein translation, increase chaperone expression and enhance ER-associated protein degradative pathways.

Among the UPR transmitters so far identified, IRE1 and PERK are both type I transmembrane protein kinases which dimerize to promote autophosphorylation and activation in response to ER stress. Activated IRE1 endonucleolytically cleaves mRNA that encodes a transcription factor named homologous to ATF/CREB1 (Hac1) in yeast [133, 134] and X-box binding protein-1 (XBP1) in higher species [135, 136]. The spliced forms of Hac1 and/or XBP1 in turn activate the transcription of the UPR target genes. In contrast, activated PERK phosphorylates the -subunit of eukaryotic translation initiation factor-2 (eIF2 ) which leads to lower levels of eIF2 and translational suppression [137]. The PERK-eIF2 signaling pathway also activates the transcription of the UPR target genes through CAP-independent upregulation of the translation of a transcription factor ATF4 [138]. PERK can also directly phosphorylate and activate the transcription factor, NF-E2-related factor-2 (Nrf2), which contributes to cellular redox homeostatis by inducing the expression of anti-oxidant genes [139, 140]. ATF6 is a type II transmembrane protein which is cleaved by Golgi apparatus-resident proteases site-1 protease (SP1) and site-2 protease (SP-2) in response to ER stress [141, 142]. The cleaved N-terminal fragment of ATF6 acts as a transcription factor to increase the transcription of the UPR target genes together with XBP1 and ATF4.

UPR signaling generally promotes cell survival by improving the balance between the protein load and the folding capacity in the ER and/or by improving the secretion of trophic factors/growth factors [143, 144]. However, if the protein load in the ER exceeds its folding capacity, or some defects in the UPR exist, cells tend to die, typically, with apoptotic features (ER stress-induced cell death). Although the exact molecular mechanisms that regulate this type of cell death remain to be elucidated, at least three pathways have been identified as being involved: the caspase-12/caspase-4 pathway and CHOP and IRE1-JNK pathways. Caspase-12 [145] in mice and caspase-4 in human [146] have been proposed as caspases that initiate ER stress-induced cell death. Caspase-12 null mice are reported to be relatively resistant to ER stress and amyloid-beta toxicity [145]. Caspase-12 is reported to directly cleave procaspase-9 without involvement of the cytochrome c/Apaf-1 pathway [147]. C/EBP homologous protein (CHOP), a transcription factor that is induced downstream of PERK and ATF6 pathways, induces ER stress-induced cell death at least in part by suppressing the expression of Bcl-2 [148] and inducing Bim expression [149]. IRE1 also participates in ER stress-induced cell death by activating JNK through the binding with ASK1 and Traf2 [150, 151].

Important roles for ER stress and ER stress-induced cell death have also been demonstrated in a broad spectrum of pathophysiological situations, including ischemia, diabetes, atherosclerosis, endocrine defects, development, neurodegenerative disorders, and cancer as described below [143, 144, 152–155].

Among the UPR targets, glucose-regulated proteins (GRPs) are the most studied and best characterized. GRPs were originally identified as proteins induced by glucose starvation [156]. Later, it was found that these molecules were transcriptionally induced by ER stress through the cis-acting element termed ER stress response element (ERSE) [157]. GRPs include molecular chaperones in the ER such as GRP78/Bip, GRP94, ORP150/GRP170, and oxidoreductases in the ER such as PDI, ERp72, and GRP58/ERp57. Accumulating evidence suggests that GRPs promote cell survival when exposed to stresses such as hypoxia/ischemia [143, 158], glutamate excitotoxicity [159], and neurodegeneration [160–162]. GRP78 could be a potential factor to inhibit atherosclerosis by preventing ER stress-induced cell death in endothelial cells [163]. This involves the inhibition of the activation of SREBPs, a molecule that induces cholesterol and triglyceride biosynthesis, or by inhibiting tissue factor procoagulant activity [164–166]. ORP150/GRP170 was found to be associated with insulin sensitivity in both human and mice as described below. Furthermore, GRPs also play important roles in survival during early mammalian development [159, 167–169].

Interestingly, recent studies have revealed that small compounds that mimic the functions of GRPs (chemical chaperones) and those that induce endogenous GRPs (molecular chaperone inducers) can prevent protein aggregation [170], improve protein secretion [171], and protect cells against brain ischemia [172] or neurodegeneration [173]. These results suggest that the regulation of ER stress can be a novel therapeutic target in a variety of diseases.

3.3. The DNA Damage Response

Upon cellular stress conditions that are caused by exposure to chemotherapeutic agents, irradiation, or environmental genotoxic agents such as polycyclic hydrocarbons or ultraviolet (UV) light, damage to DNA is a common initial event [174, 175]. DNA double strand breaks (DSBs) and single strand breaks (SSBs) are considered as key lesions that initiate the activation of the DNA damage response [174]. Since the DNA duplex is more vulnerable to chemical attack or nucleases when it is separated into two single-stranded DNA strands, for example, during DNA replication and transcription, SSBs are preferentially generated under these conditions [176]. Defined SSBs are also generated during distinct pathways of DNA repair, for example, in the course of nucleotide excision repair (NER). After DNA damage recognition, dual incision

to the DNA lesion by ERCC1-XPF and to the damage by XPG results in the removal of the lesion-containing oligonucleotide [177]. DSBs are produced directly or indirectly by many anticancer drugs, including DNA intercalating, alkylating or crosslinking agents, topoisomerase inhibitors, and nucleotide analogs [174]. Once DSBs are generated, ataxia telangiectasia mutated (ATM) is recruited by the MRE-11-Rad50-NBS1 (MRN) complex to sites of broken DNA and phosphorylates downstream substrates such as checkpoint kinase 2 (Chk2) and p53 [175, 178] (Figure 3). p53 induces transcriptional activation of different functional programs, for example, cell cycle regulatory proteins such as p21 and pro-apoptotic factors such as CD95, PUMA, and BAX [179]. In addition, recent studies have also defined a nontranscriptional pro-apoptotic activity of p53 that regulates the intrinsic mitochondria-mediated pathway of apoptosis [180]. Damage to DNA engages DNA repair processes to ensure the cell’s survival in the case of sublethal damage [174]. Alternatively, if the damage is too severe to be repaired—the DNA-damaging insult is transmitted by the cellular stress response to the activation of effector systems to mediate cell death [174]. In the latter case, various stress-inducible molecules, including NF-κB, p53, JNK, or MAPK/ERK, have been implicated in propagating and modulating the cell death signal [81, 82].

DNA damage responses and cell death. Upon exposure to ionizing radiation or genotoxins, the damage to DNA is a common initial event. DNA double strand breaks (DSBs) or single strand breaks (SSBs) are considered to be key lesions that initiate activation of the DNA damage response. Upon DSBs, ataxia telangiectasia mutated (ATM) is recruited by the MRE-11-Rad50-NBS1 (MRN) complex to sites of broken DNA and phosphorylates downstream substrates such as checkpoint kinase 2 (Chk2), which subsequently phosphorylates p53. Sublethal damage to DNA can engage survival pathways via p21-mediated cell cycle arrest. Alternatively—if the damage is too severe to be repaired—pro-apoptotic p53 target genes are activated including Bax, Puma, Noxa, and Fas, which promote apoptosis. Upon SSBs, it is ataxia telangiectasia and Rad3 related (ATR) that gets activated and phosphorylates Chk1. Chk1 in turn phosphorylates and inhibits cdc25c to mediated G2/M arrest or alternatively cdc25a to promote S-phase arrest.

Depending on the type of lesion, DNA damage initiates one of several mammalian DNA repair pathways, which eventually restore the continuity of the DNA double strand. There are two main pathways for the repair of DSBs, that is, nonhomologous end-joining and homologous recombination [181, 182]. The former constitutes the predominant DNA repair pathway in humans and involves DNA repair proteins such as DNA-PK, Ku70, and Ku80 [181, 182]. Base damage can be repaired either by enzyme-catalyzed reversal or alternatively via excision repair [183]. Mismatch repair is responsible for the removal of incorrectly paired nucleotides [184]. It is important to note that DNA repair can, in principle, be error-free and error-prone. Several proteins have been discovered recently that exert a specific function in error-free repair processes to guarantee high-fidelity reconstitution of the DNA [185]. Faithful genome transmission requires the coordination of this highly complex network of DNA repair pathways and repair surveillance mechanisms linked to cell cycle checkpoints as well as cell death mechanisms [185]. Error-prone repair or complete failure of DNA repair cannot only lead to mutations but can also lead to the initiation of cell death pathways [185].

3.4. The Response to Oxidative Stress

Cell survival requires appropriate proportions of molecular oxygen and various antioxidants. Reactive products of oxygen are amongst the most potent and omnipresent threats faced by cells. These include ROS such as superoxide anion (

), hydrogen peroxide (H2O2), singlet oxygen, hydroxyl radical (OH • ), peroxy radical, as well as the second messenger nitric oxide (NO • ) which can react with to form peroxynitrite (ONOO − ). Normally in cells there exists equilibrium between pro-oxidant species and antioxidant defense mechanisms such as ROS-metabolizing enzymes including catalase, glutathione peroxidase, and superoxide dismutases (SODs) and other antioxidant proteins such as glutathione (GSH) (Figure 4). Oxidative stress occurs when there is a disturbance in this pro-oxidant:antioxidant balance and it has been implicated in several biological and pathological processes [186]. Although most oxidative insults can be overcome by the cell’s natural defenses, sustained perturbation of this balance may result in either apoptotic or necrotic cell death [186–190].

Oxidative stress and cell death. There is a plethora of stimuli that can trigger the generation of reactive oxygen species (ROS), among them irradiation, toxins, and also normal metabolic processes. A range of different ROS species have been identified, which are kept in check by antioxidant defenses. These include several detoxifying enzymes, for example, catalase, GSH peroxidase, and superoxide dismutase (SOD). If these antioxidants defense mechanisms are too weak, ROS-mediated damage to cellular macromolecules will eventually lead to cell death.

ROS can emanate from intracellular or extracellular sources. Auto-oxidation of reduced respiratory components of the mitochondrial electron transport chain causes the production of free radical intermediates, and H2O2, which in the presence of iron can produce highly reactive OH • radical via the Fenton reaction. These ROSs are dealt with by SODs, enzymes considered to be the first line of defense against oxygen toxicity. ROS can also be produced in the cytosol. For example, the arachidonic acid cascade, yielding prostaglandins, and leukotrienes may generate ROS when the released lipid is metabolized [191], and some cytochrome P-450 isozymes are well-known ROS producers [192]. Also, the auto-oxidation reactions of ascorbic acid, low molecular weight thiols, adrenalin, and flavin coenzymes can cause ROS production. In many of these cases, cytosolic GSH neutralizes the offenders. In addition to physiological sources of ROS, diverse exogenous agents can contribute to the intracellular production of free radicals. Most of these compounds cause the generation of and H2O2 [80, 193, 194]. The mechanism of action of many exogenous agents involves redox cycling whereby an electron is accepted to form a free radical and it is then transferred to oxygen.

Interestingly, there is evidence of cross-talk between oxidative stress and other stress response pathways. For example, oxidative stress is known to cause an increase in the expression of certain inducible Hsps, particularly Hsp27 [195–197]. Hsps have been reported to protect against many stresses apart from heat shock, including heavy metals, radiation, nitric oxide, and other oxidants. In addition, activation of the UPR stimulates upregulation of antioxidant genes through PERK-dependent phosphorylation of the Nrf2 transcription factor, whose target genes include enzymes involved in GSH biosynthesis, and heme oxygenase-1 [198]. Moreover, perturbations in cellular redox status sensitize cells to the harmful effects of ER stress [199]. Similarly, accumulating evidence suggests a role for in the activation of autophagy [200].

ROS can cause damage to all of the major classes of biological macromolecules, including nucleic acids, proteins, carbohydrates, and lipids. When the cell’s antioxidant defenses are overwhelmed, ROS can induce cell death. Numerous, recent studies have shown that the mode of cell death that occurs depends on the severity of the insult [187–189]. In fact, oxidants and antioxidants not only determine cell fate, but can also modulate the mode of cell death [186, 190].

Many cytotoxic agents induce ROS, including peroxide and , which are involved in the induction of apoptotic cell death [201]. H2O2 can cause the release of cytochrome c from mitochondria into the cytosol and H2O2 may also activate nuclear transcription factors, like NF-κB, AP-1, and p53 [202], which may upregulate death proteins or produce inhibitors of survival proteins. One model proposed for H2O2 induction of apoptosis is upregulation of the Fas-FasL system, leading to activation of caspase-8 and downstream caspases [203, 204]. It is also possible that NO • may also inactivate several antioxidant enzymes, including catalase, glutathione peroxidase, and superoxide dismutases [205, 206]. Also, NO • has been reported to induce apoptosis by increasing ceramide generation through caspase-3 activation, induction of mitochondrial permeability transition, and activation of the Fas system [207].

Certain anti-apoptotic proteins have also been reported to have antioxidant roles. An early suggestion regarding the mechanism of action of Bcl-2 was that it inhibited cell death by reducing the generation of reactive oxidants, thus preventing critical intracellular oxidations that are requisite for the completion of the apoptotic program [208]. However, it is now understood that the reduction in ROS observed with Bcl-2 overexpression is probably the result of its ability to prevent loss of cytochrome c from mitochondria. Yet it is interesting to note that separate studies illustrate that Bcl-2-overexpressing cells have higher levels of total cellular GSH [209]. The product of the baculovirus p35 gene, a potent anti-apoptotic protein, is thought to have antioxidant role and is protective against many apoptotic stimuli including growth factor withdrawal, staurosporine, glucocorticoid, and actinomycin-D treatment, and is a broad-spectrum caspase inhibitor [210]. However, caspase inhibition may not be p35’s sole mechanism of cytoprotection. Expression of the p35 gene inhibits H2O2-induced apoptosis in insect cells and may be acting as a sink for free radicals [211].

However, ROS are also reported to interfere with the apoptosis death program, compelling cells to adopt an alternative mode of cell death. Apoptotic cell death can be switched to necrosis during oxidative stress by two possible mechanisms: inactivation of caspases or a drop in cellular levels of ATP levels. Caspases contain an active site cysteine nucleophile [212] which is prone to oxidation or thiol alkylation as well as S-nitrosylation [80, 213, 214]. This leads to their inactivation, switching the mode of cell death to necrosis [80, 214]. NO • may act as a molecular switch to control protein function via reactive thiol groups. For example, NO • -mediated inhibition of apoptosis in most cases is due to direct inhibition of caspase activity through S-nitrosylation of the active site cysteine conserved in all caspases although indirect effects on caspases can also be a component of toxicity in certain systems [214]. A switch from apoptosis to necrosis can also occur due to a drop in cellular levels of ATP caused by the failure of mitochondrial energy production by oxidants [215, 216]. As mentioned previously ROS may provide a common link between cellular stress signals and the initiation of autophagy, and ROS accumulation has been reported to result in inactivation of the cysteine protease ATG4, which in turn causes accumulation of the ATG8-phosphoethanolamine precursor that is required for the initiation of autophagosome formation [44]. In most circumstances, the induction of an autophagic response serves as a strategy that should ensure the cell’s survival [217]. Under certain conditions, however, it may also bring about cell death, although the molecular determinants that may control the switch from survival to death are still poorly defined. In fact, in response to several anticancer drugs ROS can induce autophagic cell death.

4. Switch from Prosurvival Signaling to Cell Death Signaling

While conditions of stress stimulate cells to mount protective responses to counteract the effect of the stress on cellular processes, if the stress remains unresolved, eventual death of the cell ensues. This raises key questions about the molecular mechanisms involved in this switch from prosurvival signaling to prodeath signaling. For example, is there a particular molecule that acts as a molecular switch? How do the duration and severity of the stress contribute to activation of this switch? As described above, in the face of exposure to cell stress, the cell mounts protective responses such as the heat shock response, or the unfolded protein response, in order to relieve the stress and promote survival. However, it is known that if the stress is very severe or if it is prolonged, the cell will die in spite of the activation of prosurvival signaling.

In the case of the response of cells to heat stress, the induction of Hsps does not occur if the stress is too severe and it has previously been suggested that the induction of thermotolerance, that is, Hsp expression, and of cell death is mutually exclusive events within the same cell [87, 195]. In support of this, we have observed that in a culture exhibiting mixed responses to a stressor, that is, expression of Hsps, induction of apoptosis, and induction of necrosis, the expression of Hsps was mainly observed in the surviving cells [196]. However, a recent report suggests that this may not always be the case, as at least one agent, which induces expression of Hsps through direct activation of HSF1, induces apoptosis rather than being protective [218].

During ER stress, IRE1 may be involved in the switch between the prosurvival UPR and initiation of cell death pathways [219]. Interestingly, the three arms of the UPR are thought to be activated sequentially, with PERK being activated most rapidly, followed by ATF6 and then IRE1. This suggests that time is allowed so that PERK and ATF6 may resolve the stress, and although IRE1 also contributes to the prosurvival UPR, it ultimately terminates it by relieving the translational inhibition by inducing

[20]. If the stress has been resolved, the cell returns to normal, but if not, then apoptosis is initiated, possibly by IRE1-dependent activation of ASK1 and its downstream target JNK. However, recently it has been shown that attenuation of IRE1 can switch the adaptive UPR to apoptosis and that persistent activation of IRE1 increases cell viability upon ER stress, suggesting that the duration of IRE1 signaling may act as a switch [219].

5. Stress Responses in Disease States

It is currently understood that a pathological stress response is a hallmark of many common human diseases for a number of reasons. Firstly, the stress stimulus may be too strong and/or prolonged, thereby allowing insufficient time for recovery to the normal status. Secondly, a cell’s ability to handle even physiological levels of stress may be altered in disease states, similarly resulting in detrimental outcomes. In the following section, we will provide some selected examples of how pathological handling of stress is one of the major underlying causes of the pathophysiological state in very different types of human diseases.

5.1. Diabetes

Loss of function or death of the pancreatic

-cells in the Islets of Langerhans in the pancreas is the major pathological feature of diabetes mellitus. The pancreatic -cells have a highly developed secretory system, in which the ER has an integral role, enabling a rapid response to glucose stimulation by producing and releasing large amounts of insulin. Both oxidative stress and ER stress are involved in the failure of pancreatic -cells and development of diabetes.

The reactive species which play an important role in the pathogenesis of pancreatic -cell loss in diabetes are generated intracellularly when the -cells are targeted by proinflammatory cytokines in autoimmune Type 1 diabetes or when exposed to a hyperglycaemic and hyperlipidaemic milieu in Type 2 diabetes. There is evidence for the participation of both NO • and ROS in the pathogenesis of -cell death in Type 1 diabetes, whereas, for -cell dysfunction in Type 2 diabetes, ROS are the main culprits.

Proinflammatory cytokines, including IL-1 (interleukin 1 ), TNF (tumor necrosis factor ), and IFN

(interferon ), released from immune cells infiltrating the pancreas in Type 1 diabetes, target the -cells via their respective receptors [220]. They activate a multitude of signaling cascades, culminating in apoptosis of -cells [221]. A number of steps in this chain of events affect the rate of generation of NO • and ROS. It is evident from studies in patients with diabetes and in animal models of Type 1 diabetes, that IL-1 is the key proinflammatory cytokine which significantly contributes to -cell dysfunction and apoptosis in the pathogenesis of Type 1 diabetes. It does so through activation of the transcription factor NF-κB which is responsible for the induction of iNOS and subsequent production of NO • [155, 221]. The production and release of IFN acts synergistically with IL-1 . High concentrations of IFN are required to potentiate the effects of IL-1 on iNOS and NO • production [222]. NO • and ROS seem to also cross-talk with ER stress and UPR [223].

IL-1 also induces MnSOD (a manganese-dependent SOD isoenzyme) and this results in an increased rate of conversion of into H2O2 in the mitochondria [224]. Cu/ZnSOD, the cytoplasmic isoenzyme, is unaffected by IL-1 . The profile of the effects of TNF and IFN alone, or in combination with IL-1 , on MnSOD is comparable with that of their regulation of iNOS. The effects on the generation of both radicals are not only important in themselves but also affect the balance between NO • and , and this can have significant effects on -cell toxicity. A decrease in through MnSOD may present as a protective signal through a reduction of NF-κB activation and other components of the IL-1 signaling pathway [225]. On the other hand, an increased conversion rate of into H2O2 by SOD is likely to increase toxicity to the -cell with its poor enzymatic capacity for H2O2 inactivation [226, 227].

Another major proinflammatory cytokine, TNF , is released from the infiltrating immune cells speeds up -cell loss significantly, resulting in an accelerated progression of the disease with rapid loss of the entire pancreatic -cell population and Islet mass. Ceramide is likely to play a significant role as a mediator of formation in TNF -mediated toxicity [228], thereby explaining the dominance of ROS in the case of TNF when compared with IL-1 . Thus, with a significant contribution of TNF produced by the infiltrating immune cells in Type 1 diabetes the resulting greater cytotoxicity is the result of the more pronounced ROS component of TNF toxicity.

That the ROS-mediated component of cytokine toxicity primarily targets the mitochondria is shown by the fact that exposure of insulin-producing cells to IL-1 , or to a cytokine mixture containing both IFN and TNF , causes mitochondrial damage, while other subcellular structures remain intact. This damage can be prevented by expression of high levels of catalase or GSH in the mitochondria, but not in the cytosol [228]. IL-1 toxicity, mediated through NO • and potentiated by IFN and TNF , is likely to focus its effects in the cytoplasm. This component will presumably contribute to ER stress, which plays a significant role in dysfunction of -cells under cytokine attack [229].

-Cell loss in Type 2 diabetes is slower than in Type 1 diabetes, typically with a long phase of -cell dysfunction, characterized by defective insulin secretion in response to glucose. In Type 2 diabetes, glucolipotoxicity, rather than proinflammatory cytokines, is considered to be an important contributing factor to -cell dysfunction [230–234]. It is evident from studies on -cells exposed to a combination of high glucose and a saturated fatty acid that NO • generation through iNOS induction does not contribute to -cell dysfunction [235].

Increased mitochondrial metabolic flux is required in the -cell for generation of the ATP signal for glucose-induced insulin secretion [236] and its potentiation through fatty acids [231]. On the other hand, increased metabolic flux through the respiratory chain at high glucose and lipid concentrations should increase formation, thereby reducing the mitochondrial membrane potential via uncoupling protein 2 [230, 237]. This should decrease metabolic flux through the respiratory chain and thus reduce production, thereby acting in a protective manner against ROS-induced damage, but, at the same time, attenuating nutrient-induced insulin secretion. This casts doubt on the concept that increased intra-mitochondrial generation of ROS crucially contributes to -cell damage in Type 2 diabetes.

This interpretation is supported by the results of morphological analyses showing that insulin-producing cells exposed to the fatty acid palmitate show no signs of mitochondrial damage, but very pronounced defects of the ER [238], confirming observations of increased ER stress in response to glucolipotoxicity [235]. Thus one of the prominent targets of this free-radical-mediated toxicity might indeed be the ER.

Defects in PERK-eIF2 pathways cause Wolcott-Rallison syndrome, a rare infantile-onset insulin-requiring diabetes [239] and PERK-null mice developed similar phenotypes [240]. Mice with mutated proinsulin (proinsulin-2) that cannot form a disulfide bond (Akita mice) also develop severe diabetes which is associated with the ER stress-induced cell death in pancreatic -cells [241, 242]. Mice deficient for , which suppresses PERK-mediated phosphorylation of eIF2 , exhibit apoptosis of pancreatic -cells and diabetes [243]. This suggests that the tight regulation of PERK-eIF2 pathway is required for the maintenance of pancreatic -cells. In contrast, some single nucleotide polymorphisms (SNPs) in the ORP150/GRP170 genome of Pima Indians are associated with insulin sensitivity in peripheral tissues [244]. Accordingly, overexpression of ORP150 enhances insulin sensitivity and suppresses oxidative stress but does not improve insulin secretion [245]. These findings suggest that proper functioning of the ER is important for both insulin synthesis in pancreatic -cells and insulin sensitivity in peripheral tissues. Consistent with this hypothesis, chemical chaperones such as 4-phenylbutryic acid and tauroursodeoxycholic acid improved both insulin resistance and insulin synthesis [171, 246].

5.2. Parkinson’s Disease

Neurodegenerative diseases are characterized by the loss of subsets of neurons. The course of these diseases can last decades, with the accumulation of neuronal loss causing progressively worse symptoms. Postmortem tissue is usually obtained from end-stage patients, at which time many of the evidences regarding the events preceding cell death are long gone. However, there is substantial and growing evidence for the activation of stress responses in neurons in all of the common neurodegenerative diseases. This suggests that when neurons are exposed to stress, they counteract with activation of one or more protective stress responses however, eventually the neurons are unable to cope and one-by-one they are lost as the disease progresses. There is a growing recognition that protein misfolding and impairment of protein handling play a key role in neuronal cell death in neurodegenerative diseases [153].

As an example of stress responses and stress-induced cell death in neurodegenerative disease, we will describe the evidence pertaining to Parkinson’s disease. Parkinson’s disease is the second most common neurodegenerative disease, affecting mainly people over 55 years and causing progressively worsening motor impairment. It is characterized pathologically by the degeneration of midbrain dopaminergic neurons in the substantia nigra pars compacta and the presence of proteinaceous intracytoplasmic inclusions (Lewy bodies) within the surviving neurons.

The molecular mechanisms that initiate dopaminergic neuron loss in Parkinson’s disease are not known. Evidence from various sources suggest that environmental toxins, genetic predisposition, and aging are important factors in the onset and progression of the disease [247–249]. Insecticides such as rotenone and the mitochondrial toxin 1-Methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP) cause dopaminergic neuronal loss in animal models and have been implicated in Parkinson’s disease itself [250, 251]. To date, mutations in at least 13 PARK genes have been linked to the pathogenesis of familial Parkinson’s disease which include mutations in genes that encode the proteins -synuclein, parkin, PTEN-induced kinase 1 (PINK1), DJ-1, leucine-rich repeat kinase2 (LRRK2), Omi/Htra2, and ubiquitin carboxy-terminal hydrolase L1 (UCHL1) [252]. Of these, -synuclein (along with chaperone proteins and ubiquitin) is a major component of Lewy bodies. Parkin and UCHL1 are linked to the ubiquitin-proteasome system that degrades damaged or misfolded proteins [253]. In addition, several of these genes, including parkin, PINK1, DJ-1, and Omi/Htra2 are linked to the mitochondria and may have roles in mitochondrial function and resistance to oxidative stress [254].

Mutations in PARK genes, as well as toxins that specifically target dopaminergic neurons, have been strongly linked to the activation of stress responses in dopaminergic neurons. For example, mitochondrial dysfunction due to mutations in certain PARK genes or to environmental toxins is linked with impairment of mitochondrial complex I which causes oxidative stress in affected cells. It has long been known that oxidative stress is a feature of Parkinson’s disease and it is observed in experimental models of Parkinson’s disease and in tissues from individuals with sporadic forms of the disease [255].

Most of the evidence regarding activation of the heat shock response in Parkinson’s disease come from models. Targeted overexpression of -synuclein in mouse substantia nigra causes an increase in the expression of Hsp27, Hsp40, and Hsp70 [256, 257] and elevations in Hsp27 are observed in in vitro models of Parkinson’s disease using the neurotoxin 6-hydroxdopamine [196]. Recent findings from Parkinsonian patients have described that DnaJB6 is present in the core of Lewy bodies and is also upregulated in astrocytes [258]. DnaJB6 is one of the Hsp40 chaperones, which stabilizes the interactions of Hsp70s with their substrate proteins. In vitro and in vivo models of Parkinson’s disease demonstrate that overexpression of Hsps prevents -synuclein aggregation as well as dopaminergic neuronal cell death due to -synuclein and Parkinson mimetic toxins [216, 237, 239–242]. Interestingly, the inducibility of Hsps decreases with aging, which may contribute to the inability of aged neurons to fully protect themselves from stresses such as protein misfolding, aggregation, and oxidative stress [259].

Activation of the UPR has been reported in postmortem brain tissue from patients with Parkinson’s disease. Specifically, phosphorylated PERK and phosphorylated eIF2 have been detected in dopaminergic neurons in the substantia nigra of Parkinson’s disease patients [260]. Phospho-PERK immunoreactivity was colocalized with increased -synuclein immunoreactivity in dopaminergic neurons [260]. Supporting evidences from in vitro models of Parkinson’s disease show that 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPP + ) (Parkinson mimetic drugs) trigger ER stress in dopaminergic neurons [261, 262]. Furthermore, neuronal cultures from PERK knockout mice display an increased sensitivity to 6-hydroxydopamine [262], while a null mutation in CHOP results in a reduction in 6-hydroxydopamine-induced apoptosis in vivo [263]. However, protection was not observed in the chronic MPTP model, despite robust expression of CHOP [263].

The information from models, the genetic information, as well as analysis of postmortem tissue, when taken together, strongly connects the induction of stress responses with the loss of dopaminergic neurons in Parkinson’s disease. It is likely that the induction of stress responses is the neurons attempts at protection, which eventually fail with neuronal cell death being the inevitable outcome. Interestingly, these observations are mirrored in research findings of other common neurodegenerative diseases, including Alzheimer’s disease and Huntington’s disease, indicating the important role for protein misfolding, aggregation and formation of protein inclusions in these chronic diseases [153].

5.3. Myocardial Infarction

Cardiovascular disease (CVD), a group of disorders of the heart and the vasculature, includes high blood pressure, coronary heart disease, congestive heart failure, stroke, and congenital heart defects. Apoptotic cell death is a fundamental process in the morphogenesis of the developing heart [264, 265]. Until recently the classical view was that necrosis was the major mode of cardiomyocyte death during CVD. However, accumulating in vitro and in vivo studies provides compelling evidence that terminally differentiated cardiomyocytes, can and do undergo apoptosis [266]. Apoptosis has important pathophysiological consequences, contributing to the loss and functional abnormalities of the myocardium. Cardiomyocyte apoptosis has been reported in a variety of cardiovascular diseases, including myocardial infarction, end-stage heart failure, arrhythmogenic right ventricular dysplasia, and adriamycin-induced cardiomyopathy [267]. Animal models have been instrumental in establishing the occurrence of cardiomyocyte apoptosis and in the elucidation of the apoptotic mechanisms. Features of myocyte apoptosis were first reported in rabbit and rat heart models of MI or ischemia/reperfusion injury [268, 269]. Since these pioneering studies, apoptosis has been repeatedly observed in the injured human heart [270–274]. Due to its sporadic occurrence and the prompt clearance of apoptotic cells by phagocytosis, apoptosis in diseased tissue is grossly underestimated.

Oxidative damage mediated by free radicals is a contributing factor to ischemia/reperfusion-induced injury in cardiomyocytes [275–278]. Plasma and pericardial fluid obtained from patients with end stage heart failure have increased levels of thiobarbituric acid reactive substances, a commonly used marker of ROS production [279, 280]. Reperfusion is associated with a burst of ROS generated via the mitochondrial respiratory chain, where partial reduction of ubiquinone forms ubisemiquinone combine with oxygen to form radicals [281]. High levels of ROS can lead to mitochondrial damage and dysfunction [282] and can induce apoptosis in cardiac myocytes [275, 276].

In addition, enhanced levels of the heat shock response and UPR have been demonstrated in animal models of myocardial infarction, and overexpression of either Hsps or GRPs enhanced tolerance against ischemia/reperfusion injury in these models [283, 284]. Although Hsps may work upstream of caspase-3 but downstream of cytochrome c release [285], GRPs likely contribute to the maintenance of intracellular Ca 2+ homeostasis [284]. Similarly, overexpression of sarco (endo) plasmic reticulum Ca 2+- ATPase (SERCA), which regulates intracellular Ca 2+ homeostasis, improved postischemic cardiac function and decreased myocardial infarction [286].

5.4. Cancer

Since tissue homeostasis is the result of a subtle balance between proliferation on one side and cell death on the other side, changes in the rate of cell death can contribute to either the loss or gain of tissue [22]. For example, too little cell death can contribute to tumor formation and is considered to be one of the hallmarks of human cancers [287, 288]. Some oncogenic mutations block cell death pathways creating a permissive environment for genetic instability and resulting in the accumulation of gene mutations leading to tumor initiation and progression [289]. Also, evasion of cell death promotes resistance to immune-based destruction, facilitates growth factor- or hormone-independent survival, and supports anchorage-independent survival during metastasis [288]. In addition, defects in cell death programs may confer resistance to cytotoxic therapies that are currently used in the clinic for the treatment of cancer such as chemotherapy, irradiation, or immunotherapy, since the response of cancer cells to these treatment approaches is, to a large extent, due to their ability to undergo cell death in response to cytotoxic stimuli [290–292].

In principle, the signaling to apoptosis can be blocked in cancers by loss or defective function of proapoptotic molecules, aberrantly high expression of antiapoptotic proteins, and/or by the relative dominance of cell survival signaling pathways. For example, impaired death receptor expression or function has been reported in a variety of human cancers. Reduced expression of CD95 was found in drug-resistant leukemia or neuroblastoma cells, indicating that intact signaling via CD95 is linked to drug response [293, 294]. CD95 mutations have been detected in both hematological malignancies and various solid tumors [295–300]. It is interesting to note that both agonistic TRAIL receptors, that is, TRAIl-R1 and TRAIL-R2, are located on chromosome 8p, a region that is frequently lost in cancers due to heterozygosity [301, 302]. Further, a larger range of antiapoptotic proteins are reported to be expressed at high levels in malignant versus nonmalignant tissue, including death domain-containing proteins that interfere with activation of caspase-8 at the death receptor level such as cellular FLICE-Inhibitory Protein (cFLIP) and phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes-15kDa (PED/PEA-15) [303], anti-apoptotic Bcl-2 family proteins such as Bcl-2, Bcl-XL, and Mcl-1 [31] and IAPs, including XIAP, cIAP1, cIAP2, survivin and livin [304]. Alternatively, apoptosis regulators with proapoptotic functions have been reported to be lost, mutated or epigenetically silenced in cancers. Examples include epigenetic loss or homo- or heterozygous genomic deletions of caspase-8 [305], single nucleotide substitution or frameshift mutations of the bax gene in mismatch repair-deficient colon cancer or hematopoetic malignancies [306, 307], and deletion or epigenetic silencing of the bim gene [308–310].

It is also now generally accepted that the majority of tumors, due to poor vascularisation of the tumor mass, experience stressful conditions in the tumor microenvironment, including low oxygen supply, nutrient deprivation, and pH changes. These conditions activate a range of cellular stress-response pathways, including the UPR. Recent studies have shown that the UPR plays an important role in tumorigenesis [311–315]. Activation of at least one branch of the UPR has been reported in a number of cancers and many ER chaperones and UPR target genes show increased expression in human tumor samples. Although activation of the UPR has been reported in a variety of human cancers, the role of UPR in different forms of cancer is not yet fully characterized.

At present it is unclear how tumor cells adapt to long-term ER stress in vivo—whether the protective elements of the response are enhanced, the destructive components suppressed, or if the compromised apoptotic machinery is sufficient to protect them from UPR-induced apoptosis. Given that the UPR can trigger prosurvival and pro-apoptotic signals, it is important to understand how modulation of the UPR alters the balance between these processes and contributes to carcinogenesis in different cell types. The upregulation of UPR in cancers may be beneficial for the tumor cells by increasing the protein folding capacity and prolonging life.

Moreover, altered redox status can promote tumor initiation and progression by blunting cell death pathways. For example, a pro-oxidant intracellular milieu has been linked to carcinogenesis and tumor promotion. To this end, increased signaling via the PI3K/Akt pathway has been shown to result in enhanced intracellular ROS generation [316]. Similarly, cancer cells that constitutively express oncogenic Ras have been reported to harbor higher intracellular levels of and to be resistant to drug-induced apoptosis [317].

Hsps, including Hsp90, Hsp70, and Hsp27, are expressed at increased levels in many solid tumors and haematological malignancies. Since various oncogenic proteins that are critically required for the malignant transformation of cells, for example, Ras, Akt, and HER2, are client proteins of Hsp90, elevated levels of Hsp90 favor tumor initiation and promotion [318]. Similarly, the expression of Hsp27 and Hsp70 is abnormally high in cancers [319]. These chaperones participate in carcinogenesis and in cell death resistance by blocking key effector molecules of the apoptotic machinery at the pre- and post-mitochondrial level [319]. Thus, targeting Hsps, for example, with chemical inhibitors, is currently under investigation as anticancer strategy [318].

Error-prone repair or complete failure to repair DNA damage as well as inherited or acquired defects in maintenance systems of the mammalian genome can lead to mutations [185]. In addition, such deficiencies in the DNA damage response contribute substantially to carcinogenesis and promote the progression and treatment resistance of cancer [185].

6. Summary and Future Perspectives

Cellular stress responses are an integral part of normal physiology to either ensure the cell’s survival or alternatively to eliminate damaged or unwanted cells. Several distinct stress responses can be distinguished, among them the heat shock, unfolded protein, DNA damage, and oxidative stress responses. Despite individual signaling components, these different stress responses can eventually fuel into common cell death effector mechanisms, if the cell is unable to cope with the stress. Whether or not cellular stress triggers cell death or cell survival programs is determined by a set of different factors, among them the initial stress stimulus, cell type, and environmental factors. Because aberrant cellular stress responses are tightly linked to many common human diseases, a better understanding of the underlying molecular mechanisms is expected to enable us to interfere with these processes, for example, to switch such response from cell death into survival programs or vice versa, depending on the desired outcome. In addition, new insights into the mechanistic basis of stress responses will open new perspectives for the development of molecular targeted treatment approaches and thus have a great potential for drug discovery.


The authors are grateful to Drs. Sandra Healy and Sanjeev Gupta for their suggestions and comments on this manuscript. Fulda’s group is supported by grants from the Deutsche Forschungsgemeinschaft, the Bundesministerium für Bildung und Forschung, the Deutsche Krebshilfe, the EU (ApopTrain, APO-SYS), the Wilhelm Sander Stiftung, the Else-Kröner-Fresenius Stiftung, the Novartis Stiftung für therapeutische Forschung, and IAP6/18. Research in Samali and Gorman groups is financially supported by Science Foundation Ireland under Grant nos. 09/RFP/BMT2153, 09/RFP/BIC2371, and 05/IN3/B851 as well as grants from Health Research Board of Ireland (HRA/2009/59) and the Breast Cancer Campaign.


  1. R. A. Lockshin and Z. Zakeri, “Programmed cell death and apoptosis: origins of the theory,” Nature Reviews Molecular Cell Biology, vol. 2, no. 7, pp. 545–550, 2001. View at: Publisher Site | Google Scholar
  2. R. A. Lockshin and C. M. Williams, “Programmed cell death—I. Cytology of degeneration in the intersegmental muscles of the Pernyi silkmoth,” Journal of Insect Physiology, vol. 11, no. 2, pp. 123–133, 1965. View at: Google Scholar
  3. R. A. Lockshin and C. M. Williams, “Programmed cell death—IV. The influence of drugs on the breakdown of the intersegmental muscles of silkmoths,” Journal of Insect Physiology, vol. 11, no. 6, pp. 803–809, 1965. View at: Google Scholar
  4. R. A. Lockshin and C. M. Williams, “Programmed cell death—V. Cytolytic enzymes in relation to the breakdown of the intersegmental muscles of silkmoths,” Journal of Insect Physiology, vol. 11, no. 7, pp. 831–844, 1965. View at: Google Scholar
  5. B. M. Pützer, “E2F1 death pathways as targets for cancer therapy,” Journal of Cellular and Molecular Medicine, vol. 11, no. 2, pp. 239–251, 2007. View at: Publisher Site | Google Scholar
  6. J. L. V. Reeve, A. M. Duffy, T. O'Brien, and A. Samali, “Don't lose heart—therapeutic value of apoptosis prevention in the treatment of cardiovascular disease,” Journal of Cellular and Molecular Medicine, vol. 9, no. 3, pp. 609–622, 2005. View at: Google Scholar
  7. A. Samali, “A tribute to professor Richard A. Lockshin on his 70th birthday,” Journal of Cellular and Molecular Medicine, vol. 11, no. 6, pp. 1210–1211, 2007. View at: Publisher Site | Google Scholar
  8. Z. Zakeri, W. Bursch, M. Tenniswood, and R. A. Lockshin, “Cell death: programmed, apoptosis, necrosis, or other?” Cell Death and Differentiation, vol. 2, no. 2, pp. 87–96, 1995. View at: Google Scholar
  9. J. F. Kerr, A. H. Wyllie, and A. R. Currie, “Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics,” British Journal of Cancer, vol. 26, no. 4, pp. 239–257, 1972. View at: Google Scholar
  10. J. F. Kerr, “Shrinkage necrosis: a distinct mode of cellular death,” Journal of Pathology, vol. 105, no. 1, pp. 13–20, 1971. View at: Google Scholar
  11. B. F. Trump, P. J. Goldblatt, and R. E. Stowell, “An electron microscopic study of early cytoplasmic alterations in hepatic parenchymal cells of mouse liver during necrosis in vitro (autolysis),” Laboratory Investigation, vol. 11, pp. 986–1015, 1962. View at: Google Scholar
  12. M. Berenbom, P. I. Chang, H. E. Betz, and R. E. Stowell, “Chemical and enzymatic changes associated with mouse liver necrosis in vitro,” Cancer Research, vol. 15, no. 1, pp. 1–5, 1955. View at: Google Scholar
  13. B. C. Trauth, C. Klas, A. M. J. Peters et al., “Monoclonal antibody-mediated tumor regression by induction of apoptosis,” Science, vol. 245, no. 4915, pp. 301–305, 1989. View at: Google Scholar
  14. J. Yang, X. Liu, K. Bhalla et al., “Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked,” Science, vol. 275, no. 5303, pp. 1129–1132, 1997. View at: Publisher Site | Google Scholar
  15. D. L. Vaux, S. Cory, and J. M. Adams, “Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells,” Nature, vol. 335, no. 6189, pp. 440–442, 1988. View at: Google Scholar
  16. D. Hockenbery, G. Nunez, C. Milliman, R. D. Schreiber, and S. J. Korsmeyer, “Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death,” Nature, vol. 348, no. 6299, pp. 334–336, 1990. View at: Publisher Site | Google Scholar
  17. N. Itoh, S. Yonehara, A. Ishii et al., “The polypeptide encoded by the cDNA for human cell surface antigen fas can mediate apoptosis,” Cell, vol. 66, no. 2, pp. 233–243, 1991. View at: Google Scholar
  18. J. Yuan, S. Shaham, S. Ledoux, H. M. Ellis, and H. R. Horvitz, “The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 β -converting enzyme,” Cell, vol. 75, no. 4, pp. 641–652, 1993. View at: Publisher Site | Google Scholar
  19. R. M. Kluck, E. Bossy-Wetzel, D. R. Green, and D. D. Newmeyer, “The release of cytochrome c from mitochondria: a primary site for Bcl- 2 regulation of apoptosis,” Science, vol. 275, no. 5303, pp. 1132–1136, 1997. View at: Publisher Site | Google Scholar
  20. E. Szegezdi, S. E. Logue, A. M. Gorman, and A. Samali, “Mediators of endoplasmic reticulum stress-induced apoptosis,” EMBO Reports, vol. 7, no. 9, pp. 880–885, 2006. View at: Publisher Site | Google Scholar
  21. A. Samali, B. Zhivotovsky, D. Jones, S. Nagata, and S. Orrenius, “Apoptosis: cell death defined by caspase activation,” Cell Death and Differentiation, vol. 6, no. 6, pp. 495–496, 1999. View at: Google Scholar
  22. R. A. Lockshin and Z. Zakeri, “Cell death in health and disease,” Journal of Cellular & Molecular Medicine, vol. 11, no. 6, pp. 1214–1224, 2007. View at: Publisher Site | Google Scholar
  23. A. Samali, A. M. Gorman, and T. G. Cotter, “Apoptosis—the story so far,” Experientia, vol. 52, no. 10-11, pp. 933–941, 1996. View at: Google Scholar
  24. R. T. Bree, C. Stenson-Cox, M. Grealy, L. Byrnes, A. M. Gorman, and A. Samali, “Cellular longevity: role of apoptosis and replicative senescence,” Biogerontology, vol. 3, no. 4, pp. 195–206, 2002. View at: Publisher Site | Google Scholar
  25. A. Degterev, M. Boyce, and J. Yuan, “A decade of caspases,” Oncogene, vol. 22, no. 53, pp. 8543–8567, 2003. View at: Publisher Site | Google Scholar
  26. A. Ashkenazi, “Targeting the extrinsic apoptosis pathway in cancer,” Cytokine and Growth Factor Reviews, vol. 19, no. 3-4, pp. 325–331, 2008. View at: Publisher Site | Google Scholar
  27. A. Samali, “Apoptosis: a mapped path to cell death,” Journal of Cellular and Molecular Medicine, vol. 11, no. 6, pp. 1212–1213, 2007. View at: Publisher Site | Google Scholar
  28. G. Kroemer, L. Galluzzi, and C. Brenner, “Mitochondrial membrane permeabilization in cell death,” Physiological Reviews, vol. 87, no. 1, pp. 99–163, 2007. View at: Publisher Site | Google Scholar
  29. H. Zou, Y. Li, X. Liu, and X. Wang, “An APAf-1 · cytochrome C multimeric complex is a functional apoptosome that activates procaspase-9,” Journal of Biological Chemistry, vol. 274, no. 17, pp. 11549–11556, 1999. View at: Publisher Site | Google Scholar
  30. E. C. LaCasse, D. J. Mahoney, H. H. Cheung, S. Plenchette, S. Baird, and R. G. Korneluk, “IAP-targeted therapies for cancer,” Oncogene, vol. 27, no. 48, pp. 6252–6275, 2008. View at: Publisher Site | Google Scholar
  31. J. M. Adams and S. Cory, “The Bcl-2 apoptotic switch in cancer development and therapy,” Oncogene, vol. 26, no. 9, pp. 1324–1337, 2007. View at: Publisher Site | Google Scholar
  32. A. Letai, M. C. Bassik, L. D. Walensky, M. D. Sorcinelli, S. Weiler, and S. J. Korsmeyer, “Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics,” Cancer Cell, vol. 2, no. 3, pp. 183–192, 2002. View at: Publisher Site | Google Scholar
  33. L. Chen, S. N. Willis, A. Wei et al., “Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function,” Molecular Cell, vol. 17, no. 3, pp. 393–403, 2005. View at: Publisher Site | Google Scholar
  34. S. N. Willis, J. I. Fletcher, T. Kaufmann et al., “Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak,” Science, vol. 315, no. 5813, pp. 856–859, 2007. View at: Publisher Site | Google Scholar
  35. E. Varfolomeev and D. Vucic, “(Un)expected roles of c-IAPs in apoptotic and NF κ B signaling pathways,” Cell Cycle, vol. 7, no. 11, pp. 1511–1521, 2008. View at: Google Scholar
  36. E.-L. Eskelinen, “New insights into the mechanisms of macroautophagy in Mammalian cells,” International Review of Cell and Molecular Biology, vol. 266, pp. 207–247, 2008. View at: Publisher Site | Google Scholar
  37. X. H. Liang, S. Jackson, M. Seaman et al., “Induction of autophagy and inhibition of tumorigenesis by beclin 1,” Nature, vol. 402, no. 6762, pp. 672–676, 1999. View at: Publisher Site | Google Scholar
  38. Y. Ohsumi, “Molecular dissection of autophagy: two ubiquitin-like systems,” Nature Reviews Molecular Cell Biology, vol. 2, no. 3, pp. 211–216, 2001. View at: Publisher Site | Google Scholar
  39. Y. Kabeya, N. Mizushima, T. Ueno et al., “LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing,” EMBO Journal, vol. 19, no. 21, pp. 5720–5728, 2000. View at: Google Scholar
  40. J. J. Lum, D. E. Bauer, M. Kong et al., “Growth factor regulation of autophagy and cell survival in the absence of apoptosis,” Cell, vol. 120, no. 2, pp. 237–248, 2005. View at: Publisher Site | Google Scholar
  41. U. B. Pandey, Z. Nie, Y. Batlevi et al., “HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS,” Nature, vol. 447, no. 7146, pp. 859–863, 2007. View at: Publisher Site | Google Scholar
  42. M. Høyer-Hansen, L. Bastholm, P. Szyniarowski et al., “Control of macroautophagy by calcium, calmodulin-dependent kinase kinase- ß , and Bcl-2,” Molecular Cell, vol. 25, no. 2, pp. 193–205, 2007. View at: Publisher Site | Google Scholar
  43. M. Ogata, S.-I. Hino, A. Saito et al., “Autophagy is activated for cell survival after endoplasmic reticulum stress,” Molecular & Cellular Biology, vol. 26, no. 24, pp. 9220–9231, 2006. View at: Publisher Site | Google Scholar
  44. R. Scherz-Shouval, E. Shvets, E. Fass, H. Shorer, L. Gil, and Z. Elazar, “Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4,” EMBO Journal, vol. 26, no. 7, pp. 1749–1760, 2007. View at: Publisher Site | Google Scholar
  45. A. Nakai, O. Yamaguchi, T. Takeda et al., “The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress,” Nature Medicine, vol. 13, no. 5, pp. 619–624, 2007. View at: Publisher Site | Google Scholar
  46. R. S. Decker and K. Wildenthal, “Lysosomal alterations in hypoxic and reoxygenated hearts. I. Ultrastructural and cytochemical changes,” American Journal of Pathology, vol. 98, no. 2, pp. 425–444, 1980. View at: Google Scholar
  47. S. Khan, F. Salloum, A. Das, L. Xi, G. W. Vetrovec, and R. C. Kukreja, “Rapamycin confers preconditioning-like protection against ischemia-reperfusion injury in isolated mouse heart and cardiomyocytes,” Journal of Molecular and Cellular Cardiology, vol. 41, no. 2, pp. 256–264, 2006. View at: Publisher Site | Google Scholar
  48. S. Shimizu, T. Kanaseki, N. Mizushima et al., “Role of Bcl-2 family proteins in a non-apoptopic programmed cell death dependent on autophagy genes,” Nature Cell Biology, vol. 6, no. 12, pp. 1221–1228, 2004. View at: Publisher Site | Google Scholar
  49. L. Yu, A. Alva, H. Su et al., “Regulation of an ATG7-beclin 1 program of autophaglic cell death by caspase-8,” Science, vol. 304, no. 5676, pp. 1500–1502, 2004. View at: Publisher Site | Google Scholar
  50. E. Ullman, Y. Fan, M. Stawowczyk, H. M. Chen, Z. Yue, and W. X. Zong, “Autophagy promotes necrosis in apoptosis-deficient cells in response to ER stress,” Cell Death and Differentiation, vol. 15, no. 2, pp. 422–425, 2008. View at: Publisher Site | Google Scholar
  51. P. Boya, R. A. González-Polo, N. Casares et al., “Inhibition of macroautophagy triggers apoptosis,” Molecular & Cellular Biology, vol. 25, no. 3, pp. 1025–1040, 2005. View at: Publisher Site | Google Scholar
  52. S. Pattingre, A. Tassa, X. Qu et al., “Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy,” Cell, vol. 122, no. 6, pp. 927–939, 2005. View at: Publisher Site | Google Scholar
  53. U. Akar, A. Chaves-Reyez, M. Barria et al., “Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells,” Autophagy, vol. 4, no. 5, pp. 669–679, 2008. View at: Google Scholar
  54. S. Erlich, L. Mizrachy, O. Segev et al., “Differential interactions between Beclin 1 and Bcl-2 family members,” Autophagy, vol. 3, no. 6, pp. 561–568, 2007. View at: Google Scholar
  55. M. C. Maiuri, A. Criollo, E. Tasdemir et al., “BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-XL,” Autophagy, vol. 3, no. 4, pp. 374–376, 2007. View at: Google Scholar
  56. M. C. Maiuri, G. Le Toumelin, A. Criollo et al., “Functional and physical interaction between Bcl- X L and a BH3-like domain in Beclin-1,” EMBO Journal, vol. 26, no. 10, pp. 2527–2539, 2007. View at: Publisher Site | Google Scholar
  57. A. Oberstein, P. D. Jeffrey, and Y. Shi, “Crystal structure of the Bcl- X L -beclin 1 peptide complex: beclin 1 is a novel BH3-only protein,” Journal of Biological Chemistry, vol. 282, no. 17, pp. 13123–13132, 2007. View at: Publisher Site | Google Scholar
  58. N. Vanlangenakker, T. V. Berghe, D. V. Krysko, N. Festjens, and P. Vandenabeele, “Molecular mechanisms and pathophysiology of necrotic cell death,” Current Molecular Medicine, vol. 8, no. 3, pp. 207–220, 2008. View at: Publisher Site | Google Scholar
  59. P. Golstein and G. Kroemer, “Cell death by necrosis: towards a molecular definition,” Trends in Biochemical Sciences, vol. 32, no. 1, pp. 37–43, 2007. View at: Publisher Site | Google Scholar
  60. J. Hitomi, D. E. Christofferson, A. Ng et al., “Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway,” Cell, vol. 135, no. 7, pp. 1311–1323, 2008. View at: Publisher Site | Google Scholar
  61. W. X. Zong, D. Ditsworth, D. E. Bauer, Z. Q. Wang, and C. B. Thompson, “Alkylating DNA damage stimulates a regulated form of necrotic cell death,” Genes and Development, vol. 18, no. 11, pp. 1272–1282, 2004. View at: Publisher Site | Google Scholar
  62. M. Ankarcrona, J. M. Dypbukt, E. Bonfoco et al., “Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function,” Neuron, vol. 15, no. 4, pp. 961–973, 1995. View at: Google Scholar
  63. C. Zhu, X. Wang, F. Xu et al., “The influence of age on apoptotic and other mechanisms of cell death after cerebral hypoxia-ischemia,” Cell Death and Differentiation, vol. 12, no. 2, pp. 162–176, 2005. View at: Publisher Site | Google Scholar
  64. N. Festjens, T. Vanden Berghe, S. Cornelis, and P. Vandenabeele, “RIP1, a kinase on the crossroads of a cell's decision to live or die,” Cell Death and Differentiation, vol. 14, no. 3, pp. 400–410, 2007. View at: Publisher Site | Google Scholar
  65. E. Meylan and J. Tschopp, “The RIP kinases: crucial integrators of cellular stress,” Trends in Biochemical Sciences, vol. 30, no. 3, pp. 151–159, 2005. View at: Publisher Site | Google Scholar
  66. N. Holler, R. Zaru, O. Micheau et al., “Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule,” Nature Immunology, vol. 1, no. 6, pp. 489–495, 2000. View at: Google Scholar
  67. F. K. Chan, J. Shisler, J. G. Bixby et al., “A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses,” Journal of Biological Chemistry, vol. 278, no. 51, pp. 51613–51621, 2003. View at: Publisher Site | Google Scholar
  68. Y. Ma, V. Temkin, H. Liu, and R. M. Pope, “NF- κ B protects macrophages from lipopolysaccharide-induced cell death: the role of caspase 8 and receptor-interacting protein,” Journal of Biological Chemistry, vol. 280, no. 51, pp. 41827–41834, 2005. View at: Publisher Site | Google Scholar
  69. A. Degterev, Z. Huang, M. Boyce et al., “Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury,” Nature Chemical Biology, vol. 1, no. 2, pp. 112–119, 2005. View at: Publisher Site | Google Scholar
  70. A. Degterev, J. Hitomi, M. Germscheid et al., “Identification of RIP1 kinase as a specific cellular target of necrostatins,” Nature Chemical Biology, vol. 4, no. 5, pp. 313–321, 2008. View at: Publisher Site | Google Scholar
  71. Z. You, S. I. Savitz, J. Yang et al., “Necrostatin-1 reduces histopathology and improves functional outcome after controlled cortical impact in mice,” Journal of Cerebral Blood Flow and Metabolism, vol. 28, no. 9, pp. 1564–1573, 2008. View at: Publisher Site | Google Scholar
  72. Y. S. Cho, S. Challa, D. Moquin et al., “Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation,” Cell, vol. 137, no. 6, pp. 1112–1123, 2009. View at: Publisher Site | Google Scholar
  73. S. He, L. Wang, L. Miao et al., “Receptor interacting protein kinase-3 determines cellular necrotic response to TNF- a ,” Cell, vol. 137, no. 6, pp. 1100–1111, 2009. View at: Publisher Site | Google Scholar
  74. D. W. Zhang, J. Shao, J. Lin et al., “RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis,” Science, vol. 325, no. 5938, pp. 332–336, 2009. View at: Publisher Site | Google Scholar
  75. K. Schulze-Osthoff, A. C. Bakker, B. Vanhaesebroeck, R. Beyaert, W. A. Jacob, and W. Fiers, “Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation,” Journal of Biological Chemistry, vol. 267, no. 8, pp. 5317–5323, 1992. View at: Google Scholar
  76. M. Kalai, G. Van Loo, T. Vanden Berghe et al., “Tipping the balance between necrosis and apoptosis in human and murine cells treated with interferon and dsRNA,” Cell Death and Differentiation, vol. 9, no. 9, pp. 981–994, 2002. View at: Publisher Site | Google Scholar
  77. F. Van Herreweghe, J. Mao, F. W. R. Chaplen et al., “Tumor necrosis factor-induced modulation of glyoxalase I activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxal-derived AGE,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 2, pp. 949–954, 2002. View at: Publisher Site | Google Scholar
  78. R. G. Hansford and D. Zorov, “Role of mitochondrial calcium transport in the control of substrate oxidation,” Molecular & Cellular Biochemistry, vol. 184, no. 1-2, pp. 359–369, 1998. View at: Google Scholar
  79. B. T. Chua, K. Guo, and P. Li, “Direct cleavage by the calcium-activated protease calpain can lead to inactivation of caspases,” Journal of Biological Chemistry, vol. 275, no. 7, pp. 5131–5135, 2000. View at: Publisher Site | Google Scholar
  80. A. Samali, H. Nordgren, B. Zhivotovsky, E. Peterson, and S. Orrenius, “A comparative study of apoptosis and necrosis in HepG2 cells: oxidant-induced caspase inactivation leads to necrosis,” Biochemical and Biophysical Research Communications, vol. 255, no. 1, pp. 6–11, 1999. View at: Publisher Site | Google Scholar
  81. C. R. Weston and R. J. Davis, “The JNK signal transduction pathway,” Current Opinion in Cell Biology, vol. 19, no. 2, pp. 142–149, 2007. View at: Publisher Site | Google Scholar
  82. N. D. Perkins and T. D. Gilmore, “Good cop, bad cop: the different faces of NF- κ B,” Cell Death and Differentiation, vol. 13, no. 5, pp. 759–772, 2006. View at: Publisher Site | Google Scholar
  83. S. Lindquist, “The heat-shock response,” Annual Review of Biochemistry, vol. 55, pp. 1151–1191, 1986. View at: Google Scholar
  84. E. A. Craig, “The heat shock response,” CRC Critical Reviews in Biochemistry, vol. 18, no. 3, pp. 239–280, 1985. View at: Google Scholar
  85. A. Samali and S. Orrenius, “Heat shock proteins: regulators of stress response and apoptosis,” Cell Stress and Chaperones, vol. 3, no. 4, pp. 228–236, 1998. View at: Publisher Site | Google Scholar
  86. A. Samali and T. G. Cotter, “Heat shock proteins increase resistance to apoptosis,” Experimental Cell Research, vol. 223, no. 1, pp. 163–170, 1996. View at: Publisher Site | Google Scholar
  87. A. Samali, C. I. Holmberg, L. Sistonen, and S. Orrenius, “Thermotolerance and cell death are distinct cellular responses to stress: dependence on heat shock proteins,” FEBS Letters, vol. 461, no. 3, pp. 306–310, 1999. View at: Publisher Site | Google Scholar
  88. G. C. Li and Z. Werb, “Correlation between synthesis of heat shock proteins and development of thermotolerance in Chinese hamster fibroblasts,” Proceedings of the National Academy of Sciences of the United States of America, vol. 79, no. 10, pp. 3218–3222, 1982. View at: Google Scholar
  89. R. I. Morimoto, P. E. Kroeger, and J. J. Cotto, “The transcriptional regulation of heat shock genes: a plethora of heat shock factors and regulatory conditions,” EXS, vol. 77, pp. 139–163, 1996. View at: Google Scholar
  90. L. Pirkkala, P. Nykänen, and L. Sistonen, “Roles of the heat shock transcription factors in regulation of the heat shock response and beyond,” FASEB Journal, vol. 15, no. 7, pp. 1118–1131, 2001. View at: Publisher Site | Google Scholar
  91. A. Shabtay and Z. Arad, “Reciprocal activation of HSF1 and HSF3 in brain and blood tissues: is redundancy developmentally related?” American Journal of Physiology, vol. 291, no. 3, pp. R566–R572, 2006. View at: Publisher Site | Google Scholar
  92. D. R. McMillan, X. Xiao, L. Shao, K. Graves, and I. J. Benjamin, “Targeted disruption of heat shock transcription factor 1 abolishes thermotolerance and protection against heat-inducible apoptosis,” Journal of Biological Chemistry, vol. 273, no. 13, pp. 7523–7528, 1998. View at: Publisher Site | Google Scholar
  93. X. Xiao, X. Zuo, A. A. Davis et al., “HSF1 is required for extra-embryonic development, postnatal growth and protection during inflammatory responses in mice,” EMBO Journal, vol. 18, no. 21, pp. 5943–5952, 1999. View at: Publisher Site | Google Scholar
  94. Y. Zhang, L. Huang, J. Zhang, D. Moskophidis, and N. F. Mivechi, “Targeted disruption of hsf1 leads to lack of thermotolerance and defines tissue-specific regulation for stress-inducible hsp molecular chaperones,” Journal of Cellular Biochemistry, vol. 86, no. 2, pp. 376–393, 2002. View at: Publisher Site | Google Scholar
  95. P. Östling, J. K. Björk, P. Roos-Mattjus, V. Mezger, and L. Sistonen, “Heat Shock Factor 2 (HSF2) contributes to inducible expression of hsp genes through interplay with HSF1,” Journal of Biological Chemistry, vol. 282, no. 10, pp. 7077–7086, 2007. View at: Publisher Site | Google Scholar
  96. I. Shamovsky and E. Nudler, “New insights into the mechanism of heat shock response activation,” Cellular and Molecular Life Sciences, vol. 65, no. 6, pp. 855–861, 2008. View at: Publisher Site | Google Scholar
  97. R. Voellmy, “On mechanisms that control heat shock transcription factor activity in metazoan cells,” Cell Stress and Chaperones, vol. 9, no. 2, pp. 122–133, 2004. View at: Publisher Site | Google Scholar
  98. M. Jäättelä, “Heat shock proteins as cellular lifeguards,” Annals of Medicine, vol. 31, no. 4, pp. 261–271, 1999. View at: Google Scholar
  99. S. Lindquist and E. A. Craig, “The heat-shock proteins,” Annual Review of Genetics, vol. 22, pp. 631–677, 1988. View at: Google Scholar
  100. C. Garrido, “Size matters: of the small HSP27 and its large oligomers,” Cell Death and Differentiation, vol. 9, no. 5, pp. 483–485, 2002. View at: Publisher Site | Google Scholar
  101. M. Jäättelä, D. Wissing, K. Kokholm, T. Kallunki, and M. Egeblad, “Hsp7O exerts its anti-apoptotic function downstream of caspase-3-like proteases,” EMBO Journal, vol. 17, no. 21, pp. 6124–6134, 1998. View at: Publisher Site | Google Scholar
  102. A. E. Kabakov and V. L. Gabai, “Heat-shock-induced accumulation of 70-kDa stress protein (HSP70) can protect ATP-depleted tumor cells from necrosis,” Experimental Cell Research, vol. 217, no. 1, pp. 15–21, 1995. View at: Publisher Site | Google Scholar
  103. P. Mehlen, X. Preville, P. Chareyron, J. Briolay, R. Klemenz, and A. P. Arrigo, “Constitutive expression of human hsp27, Drosophila hsp27, or human α B- crystallin confers resistance to TNF- and oxidative stress-induced cytotoxicity in stably transfected murine L929 fibroblasts,” Journal of Immunology, vol. 154, no. 1, pp. 363–374, 1995. View at: Google Scholar
  104. M. J. Champagne, P. Dumas, S. N. Orlov, M. R. Bennett, P. Hamet, and J. Tremblay, “Protection against necrosis but not apoptosis by heat-stress proteins in vascular smooth muscle cells: evidence for distinct modes of cell death,” Hypertension, vol. 33, no. 3, pp. 906–913, 1999. View at: Google Scholar
  105. F. U. Hartl and M. Hayer-Hartl, “Molecular chaperones in the cytosol: from nascent chain to folded protein,” Science, vol. 295, no. 5561, pp. 1852–1858, 2002. View at: Publisher Site | Google Scholar
  106. C. G. Concannon, A. M. Gorman, and A. Samali, “On the role of Hsp27 in regulating apoptosis,” Apoptosis, vol. 8, no. 1, pp. 61–70, 2003. View at: Publisher Site | Google Scholar
  107. C. G. Concannon, S. Orrenius, and A. Samali, “Hsp27 inhibits cytochrome c-mediated caspase activation by sequestering both pro-caspase-3 and cytochrome c,” Gene Expression, vol. 9, no. 4-5, pp. 195–201, 2001. View at: Google Scholar
  108. P. Pandey, R. Farber, A. Nakazawa et al., “Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3,” Oncogene, vol. 19, no. 16, pp. 1975–1981, 2000. View at: Google Scholar
  109. J.-M. Bruey, C. Ducasse, P. Bonniaud et al., “Hsp27 negatively regulates cell death by interacting with cytochrome c,” Nature Cell Biology, vol. 2, no. 9, pp. 645–652, 2000. View at: Publisher Site | Google Scholar
  110. A. Samali, J. D. Robertson, E. Peterson et al., “Hsp27 protects mitochondria of thermotolerant cells against apoptotic stimuli,” Cell Stress and Chaperones, vol. 6, no. 1, pp. 49–58, 2001. View at: Publisher Site | Google Scholar
  111. D. Chauhan, G. Li, T. Hideshima et al., “Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance,” Blood, vol. 102, no. 9, pp. 3379–3386, 2003. View at: Publisher Site | Google Scholar
  112. R. Steel, J. P. Doherty, K. Buzzard, N. Clemons, C. J. Hawkins, and R. L. Anderson, “Hsp72 inhibits apoptosis upstream of the mitochondria and not through interactions with Apaf-1,” Journal of Biological Chemistry, vol. 279, no. 49, pp. 51490–51499, 2004. View at: Google Scholar
  113. A. Saleh, S. M. Srinivasula, L. Balkir, P. D. Robbins, and E. S. Alnemri, “Negative regulation of the Apaf-1 apoptosome by Hsp70,” Nature Cell Biology, vol. 2, no. 8, pp. 476–483, 2000. View at: Publisher Site | Google Scholar
  114. H. M. Beere, B. B. Wolf, K. Cain et al., “Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome,” Nature Cell Biology, vol. 2, no. 8, pp. 469–475, 2000. View at: Publisher Site | Google Scholar
  115. E. Yu. Komarova, E. A. Afanasyeva, M. M. Bulatova, M. E. Cheetham, B. A. Margulis, and I. V. Guzhova, “Downstream caspases are novel targets for the antiapoptotic activity of the molecular chaperone Hsp70,” Cell Stress and Chaperones, vol. 9, no. 3, pp. 265–275, 2004. View at: Google Scholar
  116. E. M. Creagh, R. J. Carmody, and T. G. Cotter, “Heat shock protein 70 inhibits caspase-dependent and -independent apoptosis in Jurkat T cells,” Experimental Cell Research, vol. 257, no. 1, pp. 58–66, 2000. View at: Publisher Site | Google Scholar
  117. L. Ravagnan, S. Gurbuxani, S. A. Susin et al., “Heat-shock protein 70 antagonizes apoptosis-inducing factor,” Nature Cell Biology, vol. 3, no. 9, pp. 839–843, 2001. View at: Publisher Site | Google Scholar
  118. S. J. Charette and J. Landry, “The interaction of HSP27 with Daxx identifies a potential regulatory role of HSP27 in Fas-induced apoptosis,” Annals of the New York Academy of Sciences, vol. 926, pp. 126–131, 2000. View at: Google Scholar
  119. V. L. Gabai, J. A. Yaglom, V. Volloch et al., “Hsp72-mediated suppression of c-Jun N-terminal kinase is implicated in development of tolerance to caspase-independent cell death,” Molecular & Cellular Biology, vol. 20, no. 18, pp. 6826–6836, 2000. View at: Publisher Site | Google Scholar
  120. D. D. Mosser, A. W. Caron, L. Bourget, C. Denis-Larose, and B. Massie, “Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis,” Molecular & Cellular Biology, vol. 17, no. 9, pp. 5317–5327, 1997. View at: Google Scholar
  121. J. Park and A. Y. C. Liu, “JNK phosphorylates the HSF1 transcriptional activation domain: role of JNK in the regulation of the heat shock response,” Journal of Cellular Biochemistry, vol. 82, no. 2, pp. 326–338, 2001. View at: Publisher Site | Google Scholar
  122. H. Konishi, H. Matsuzaki, M. Tanaka et al., “Activation of protein kinase B (Akt/RAC-protein kinase) by cellular stress and its association with heat shock protein Hsp27,” FEBS Letters, vol. 410, no. 2-3, pp. 493–498, 1997. View at: Publisher Site | Google Scholar
  123. K. M. Mearow, M. E. Dodge, M. Rahimtula, and C. Yegappan, “Stress-mediated signaling in PC12 cells—the role of the small heat shock protein, Hsp27, and Akt in protecting cells from heat stress and nerve growth factor withdrawal,” Journal of Neurochemistry, vol. 83, no. 2, pp. 452–462, 2002. View at: Publisher Site | Google Scholar
  124. M. J. Rane, Y. Pan, S. Singh et al., “Heat shock protein 27 controls apoptosis by regulating Akt activation,” Journal of Biological Chemistry, vol. 278, no. 30, pp. 27828–27835, 2003. View at: Publisher Site | Google Scholar
  125. X.-B. Qiu, Y.-M. Shao, S. Miao, and L. Wang, “The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones,” Cellular & Molecular Life Sciences, vol. 63, no. 22, pp. 2560–2570, 2006. View at: Publisher Site | Google Scholar
  126. S. Takayama, D. N. Bimston, S.-I. Matsuzawa et al., “BAG-1 modulates the chaperone activity of Hsp70/Hsc70,” EMBO Journal, vol. 16, no. 16, pp. 4887–4896, 1997. View at: Publisher Site | Google Scholar
  127. M. Schröder and R. J. Kaufman, “The mammalian unfolded protein response,” Annual Review of Biochemistry, vol. 74, pp. 739–789, 2005. View at: Publisher Site | Google Scholar
  128. D. Ron and P. Walter, “Signal integration in the endoplasmic reticulum unfolded protein response,” Nature Reviews Molecular Cell Biology, vol. 8, no. 7, pp. 519–529, 2007. View at: Publisher Site | Google Scholar
  129. S. Kondo, T. Murakami, K. Tatsumi et al., “OASIS, a CREB/ATF-family member, modulates UPR signalling in astrocytes,” Nature Cell Biology, vol. 7, no. 2, pp. 186–194, 2005. View at: Publisher Site | Google Scholar
  130. K. Zhang, X. Shen, J. Wu et al., “Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response,” Cell, vol. 124, no. 3, pp. 587–599, 2006. View at: Publisher Site | Google Scholar
  131. I. Nagamori, K. Yomogida, M. Ikawa, M. Okabe, N. Yabuta, and H. Nojima, “The testes-specific bZip type transcription factor Tisp40 plays a role in ER stress responses and chromatin packaging during spermiogenesis,” Genes to Cells, vol. 11, no. 10, pp. 1161–1171, 2006. View at: Publisher Site | Google Scholar
  132. G. Liang, T. E. Audas, Y. Li et al., “Luman/CREB3 induces transcription of the endoplasmic reticulum (ER) stress response protein herp through an ER stress response element,” Molecular & Cellular Biology, vol. 26, no. 21, pp. 7999–8010, 2006. View at: Publisher Site | Google Scholar
  133. J. S. Cox and P. Walter, “A novel mechanism for regulating activity of a transcription factor that controls the unfolded protein response,” Cell, vol. 87, no. 3, pp. 391–404, 1996. View at: Publisher Site | Google Scholar
  134. K. Mori, T. Kawahara, H. Yoshida, H. Yanagi, and T. Yura, “Signalling from endoplasmic reticulum to nucleus: transcription factor with a basic-leucine zipper motif is required for the unfolded protein-response pathway,” Genes to Cells, vol. 1, no. 9, pp. 803–817, 1996. View at: Google Scholar
  135. H. Yoshida, T. Matsui, A. Yamamoto, T. Okada, and K. Mori, “XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor,” Cell, vol. 107, no. 7, pp. 881–891, 2001. View at: Publisher Site | Google Scholar
  136. M. Calfon, H. Zeng, F. Urano et al., “IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA,” Nature, vol. 415, no. 6867, pp. 92–96, 2002. View at: Publisher Site | Google Scholar
  137. H. P. Harding, Y. Zhang, and D. Ron, “Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase,” Nature, vol. 397, no. 6716, pp. 271–274, 1999. View at: Publisher Site | Google Scholar
  138. P. D. Lu, H. P. Harding, and D. Ron, “Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response,” Journal of Cell Biology, vol. 167, no. 1, pp. 27–33, 2004. View at: Publisher Site | Google Scholar
  139. S. B. Cullinan, D. Zhang, M. Hannink, E. Arvisais, R. J. Kaufman, and J. A. Diehl, “Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival,” Molecular & Cellular Biology, vol. 23, no. 20, pp. 7198–7209, 2003. View at: Publisher Site | Google Scholar
  140. S. B. Cullinan and J. A. Diehl, “PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress,” Journal of Biological Chemistry, vol. 279, no. 19, pp. 20108–20117, 2004. View at: Publisher Site | Google Scholar
  141. K. Haze, H. Yoshida, H. Yanagi, T. Yura, and K. Mori, “Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress,” Molecular Biology of the Cell, vol. 10, no. 11, pp. 3787–3799, 1999. View at: Google Scholar
  142. J. Ye, R. B. Rawson, R. Komuro et al., “ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs,” Molecular Cell, vol. 6, no. 6, pp. 1355–1364, 2000. View at: Publisher Site | Google Scholar
  143. M. Tamatani, T. Matsuyama, A. Yamaguchi et al., “ORP150 protects against hypoxia/ischemia-induced neuronal death,” Nature Medicine, vol. 7, no. 3, pp. 317–323, 2001. View at: Publisher Site | Google Scholar
  144. O. Hori, M. Miyazaki, T. Tamatani et al., “Deletion of SERP1/RAMP4, a component of the endoplasmic reticulum (ER) translocation sites, leads to ER stress,” Molecular & Cellular Biology, vol. 26, no. 11, pp. 4257–4267, 2006. View at: Publisher Site | Google Scholar
  145. T. Nakagawa, H. Zhu, N. Morishima et al., “Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid- ß ,” Nature, vol. 403, no. 6765, pp. 98–103, 2000. View at: Publisher Site | Google Scholar
  146. J. Hitomi, T. Katayama, Y. Eguchi et al., “Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and A ß -induced cell death,” Journal of Cell Biology, vol. 165, no. 3, pp. 347–356, 2004. View at: Publisher Site | Google Scholar
  147. R. V. Rao, S. Castro-Obregon, H. Frankowski et al., “Coupling endoplasmic reticulum stress to the cell death program. An Apaf-1-independent intrinsic pathway,” Journal of Biological Chemistry, vol. 277, no. 24, pp. 21836–21842, 2002. View at: Publisher Site | Google Scholar
  148. K. D. McCullough, J. L. Martindale, L.-O. Klotz, T.-Y. Aw, and N. J. Holbrook, “Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bc12 and perturbing the cellular redox state,” Molecular & Cellular Biology, vol. 21, no. 4, pp. 1249–1259, 2001. View at: Publisher Site | Google Scholar
  149. H. Puthalakath, L. A. O'Reilly, P. Gunn et al., “ER stress triggers apoptosis by activating BH3-only protein Bim,” Cell, vol. 129, no. 7, pp. 1337–1349, 2007. View at: Publisher Site | Google Scholar
  150. F. Urano, X. Wang, A. Bertolotti et al., “Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1,” Science, vol. 287, no. 5453, pp. 664–666, 2000. View at: Publisher Site | Google Scholar
  151. H. Nishitoh, A. Matsuzawa, K. Tobiume et al., “ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats,” Genes and Development, vol. 16, no. 11, pp. 1345–1355, 2002. View at: Publisher Site | Google Scholar
  152. M. Ni and A. S. Lee, “ER chaperones in mammalian development and human diseases,” FEBS Letters, vol. 581, no. 19, pp. 3641–3651, 2007. View at: Publisher Site | Google Scholar
  153. A. M. Gorman, “Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling,” Journal of Cellular & Molecular Medicine, vol. 12, no. 6, pp. 2263–2280, 2008. View at: Publisher Site | Google Scholar
  154. A. N. Mhaille, S. McQuaid, A. Windebank et al., “Increased expression of endoplasmic reticulum stress-related signaling pathway molecules in multiple sclerosis lesions,” Journal of Neuropathology & Experimental Neurology, vol. 67, no. 3, pp. 200–211, 2008. View at: Publisher Site | Google Scholar
  155. C. Holohan, E. Szegezdi, T. Ritter, T. O'Brien, and A. Samali, “Cytokine-induced β -cell apoptosis is NO-dependent, mitochondria-mediated and inhibited by BCL-XL,” Journal of Cellular & Molecular Medicine, vol. 12, no. 2, pp. 591–606, 2008. View at: Publisher Site | Google Scholar
  156. R. P. C. Shiu, J. Pouyssegur, and I. Pastan, “Glucose depletion accounts for the induction of two transformation-sensitive membrane proteins in Rous sarcoma virus-transformed chick embryo fibroblasts,” Proceedings of the National Academy of Sciences of the United States of America, vol. 74, no. 9, pp. 3840–3844, 1977. View at: Google Scholar
  157. H. Yoshida, K. Haze, H. Yanagi, T. Yura, and K. Mori, “Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins: involvement of basic leucine zipper transcription factors,” Journal of Biological Chemistry, vol. 273, no. 50, pp. 33741–33749, 1998. View at: Publisher Site | Google Scholar
  158. S. Tanaka, T. Uehara, and Y. Nomura, “Up-regulation of protein-disulfide isomerase in response to hypoxia/brain ischemia and its protective effect against apoptotic cell death,” Journal of Biological Chemistry, vol. 275, no. 14, pp. 10388–10393, 2000. View at: Publisher Site | Google Scholar
  159. Y. Kitao, K. Ozawa, M. Miyazaki et al., “Expression of the endoplasmic reticulum molecular chaperone (ORP150) rescues hippocampal neurons from glutamate toxicity,” Journal of Clinical Investigation, vol. 108, no. 10, pp. 1439–1450, 2001. View at: Publisher Site | Google Scholar
  160. T. Uehara, T. Nakamura, D. Yao et al., “S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration,” Nature, vol. 441, no. 7092, pp. 513–517, 2006. View at: Publisher Site | Google Scholar
  161. Y. Kitao, Y. Imai, K. Ozawa et al., “Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation,” Human Molecular Genetics, vol. 16, no. 1, pp. 50–60, 2007. View at: Publisher Site | Google Scholar
  162. T. Hoshino, T. Nakaya, W. Araki, K. Suzuki, T. Suzuki, and T. Mizushima, “Endoplasmic reticulum chaperones inhibit the production of amyloid- β peptides,” Biochemical Journal, vol. 402, no. 3, pp. 581–589, 2007. View at: Publisher Site | Google Scholar
  163. R. E. Feaver, N. E. Hastings, A. Pryor, and B. R. Blackman, “GRP78 upregulation by atheroprone shear stress via p38-, α 2 β 1-dependent mechanism in endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 8, pp. 1534–1541, 2008. View at: Publisher Site | Google Scholar
  164. C. Zhang, Y. Cai, M. T. Adachi et al., “Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response,” Journal of Biological Chemistry, vol. 276, no. 38, pp. 35867–35874, 2001. View at: Publisher Site | Google Scholar
  165. G. H. Werstuck, S. R. Lentz, S. Dayal et al., “Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways,” Journal of Clinical Investigation, vol. 107, no. 10, pp. 1263–1273, 2001. View at: Google Scholar
  166. L. M. Watson, A. K. C. Chan, L. R. Berry et al., “Overexpression of the 78-kDa glucose-regulated protein/immunoglobulin-binding protein (GRP78/BiP) inhibits tissue factor procoagulant activity,” Journal of Biological Chemistry, vol. 278, no. 19, pp. 17438–17447, 2003. View at: Publisher Site | Google Scholar
  167. S. Luo, C. Mao, B. Lee, and A. S. Lee, “GRP78/BiP is required for cell proliferation and protecting the inner cell mass from apoptosis during early mouse embryonic development,” Molecular & Cellular Biology, vol. 26, no. 15, pp. 5688–5697, 2006. View at: Publisher Site | Google Scholar
  168. N. Mesaeli, K. Nakamura, E. Zvaritch et al., “Calreticulin is essential for cardiac development,” Journal of Cell Biology, vol. 144, no. 5, pp. 857–868, 1999. View at: Publisher Site | Google Scholar
  169. Y. Kitao, K. Hashimoto, T. Matsuyama et al., “ORP150/HSP12A regulates purkinje cell survival: a role for endoplasmic reticulum stress in cerebellar development,” Journal of Neuroscience, vol. 24, no. 6, pp. 1486–1496, 2004. View at: Publisher Site | Google Scholar
  170. K. Kubota, Y. Niinuma, M. Kaneko et al., “Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress,” Journal of Neurochemistry, vol. 97, no. 5, pp. 1259–1268, 2006. View at: Publisher Site | Google Scholar
  171. S.-E. Choi, Y.-J. Lee, H.-J. Jang et al., “A chemical chaperone 4-PBA ameliorates palmitate-induced inhibition of glucose-stimulated insulin secretion (GSIS),” Archives of Biochemistry and Biophysics, vol. 475, no. 2, pp. 109–114, 2008. View at: Publisher Site | Google Scholar
  172. T. Kudo, S. Kanemoto, H. Hara et al., “A molecular chaperone inducer protects neurons from ER stress,” Cell Death and Differentiation, vol. 15, no. 2, pp. 364–375, 2008. View at: Publisher Site | Google Scholar
  173. K. Takano, Y. Tabata, Y. Kitao et al., “Methoxyflavones protect cells against endoplasmic reticulum stress and neurotoxin,” American Journal of Physiology, vol. 292, no. 1, pp. C353–C361, 2007. View at: Publisher Site | Google Scholar
  174. W. P. Roos and B. Kaina, “DNA damage-induced cell death by apoptosis,” Trends in Molecular Medicine, vol. 12, no. 9, pp. 440–450, 2006. View at: Publisher Site | Google Scholar
  175. M. Christmann, M. T. Tomicic, W. P. Roos, and B. Kaina, “Mechanisms of human DNA repair: an update,” Toxicology, vol. 193, no. 1-2, pp. 3–34, 2003. View at: Publisher Site | Google Scholar
  176. D. J. Richard, E. Bolderson, and K. K. Khanna, “Multiple human single-stranded DNA binding proteins function in genome maintenance: structural, biochemical and functional analysis,” Critical Reviews in Biochemistry and Molecular Biology, vol. 44, no. 2-3, pp. 98–116, 2009. View at: Publisher Site | Google Scholar
  177. L. Staresincic, A. F. Fagbemi, J. H. Enzlin et al., “Coordination of dual incision and repair synthesis in human nucleotide excision repair,” EMBO Journal, vol. 28, no. 8, pp. 1111–1120, 2009. View at: Publisher Site | Google Scholar
  178. J. W. Harper and S. J. Elledge, “The DNA damage response: ten years after,” Molecular Cell, vol. 28, no. 5, pp. 739–745, 2007. View at: Publisher Site | Google Scholar
  179. K. H. Vousden and D. P. Lane, “p53 in health and disease,” Nature Reviews Molecular Cell Biology, vol. 8, no. 4, pp. 275–283, 2007. View at: Publisher Site | Google Scholar
  180. A. V. Vaseva and U. M. Moll, “The mitochondrial p53 pathway,” Biochimica et Biophysica Acta, vol. 1787, no. 5, pp. 414–420, 2009. View at: Publisher Site | Google Scholar
  181. S. P. Jackson, “Sensing and repairing DNA double-strand breaks,” Carcinogenesis, vol. 23, no. 5, pp. 687–696, 2002. View at: Google Scholar
  182. K. Valerie and L. F. Povirk, “Regulation and mechanisms of mammalian double-strand break repair,” Oncogene, vol. 22, no. 37, pp. 5792–5812, 2003. View at: Publisher Site | Google Scholar
  183. D. E. Barnes and T. Lindahl, “Repair and genetic consequences of endogenous DNA base damage in mammalian cells,” Annual Review of Genetics, vol. 38, pp. 445–476, 2004. View at: Publisher Site | Google Scholar
  184. L. Stojic, R. Brun, and J. Jiricny, “Mismatch repair and DNA damage signalling,” DNA Repair, vol. 3, no. 8-9, pp. 1091–1101, 2004. View at: Publisher Site | Google Scholar
  185. J. H. J. Hoeijmakers, “Genome maintenance mechanisms for preventing cancer,” Nature, vol. 411, no. 6835, pp. 366–374, 2001. View at: Publisher Site | Google Scholar
  186. D. Trachootham, W. Lu, M. A. Ogasawara, N. R.-D. Valle, and P. Huang, “Redox regulation of cell survival,” Antioxidants & Redox Signaling, vol. 10, no. 8, pp. 1343–1374, 2008. View at: Publisher Site | Google Scholar
  187. B. Brune, “The intimate relation between nitric oxide and superoxide in apoptosis and cell survival,” Antioxidants & Redox Signaling, vol. 7, no. 3-4, pp. 497–507, 2005. View at: Publisher Site | Google Scholar
  188. K. Niizuma, H. Endo, and P. H. Chan, “Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival,” Journal of Neurochemistry, vol. 109, supplement 1, pp. 133–138, 2009. View at: Publisher Site | Google Scholar
  189. S. Orrenius, V. Gogvadze, and B. Zhivotovsky, “Mitochondrial oxidative stress: implications for cell death,” Annual Review of Pharmacology & Toxicology, vol. 47, pp. 143–183, 2007. View at: Publisher Site | Google Scholar
  190. M. Genestra, “Oxyl radicals, redox-sensitive signalling cascades and antioxidants,” Cellular Signalling, vol. 19, no. 9, pp. 1807–1819, 2007. View at: Publisher Site | Google Scholar
  191. P. Zaccagnino, M. Saltarella, S. D'Oria, A. Corcelli, M. S. Saponetti, and M. Lorusso, “N-arachidonylglycine causes ROS production and cytochrome c release in liver mitochondria,” Free Radical Biology & Medicine, vol. 47, no. 5, pp. 585–592, 2009. View at: Publisher Site | Google Scholar
  192. A. Sapone, A. Affatato, D. Canistro et al., “Induction and suppression of cytochrome P450 isoenzymes and generation of oxygen radicals by procymidone in liver, kidney and lung of CD1 mice,” Mutation Research, vol. 527, no. 1-2, pp. 67–80, 2003. View at: Publisher Site | Google Scholar
  193. X. Gong, R. Gutala, and A. K. Jaiswal, “Quinone oxidoreductases and vitamin K metabolism,” Vitamins and Hormones, vol. 78, pp. 85–101, 2008. View at: Publisher Site | Google Scholar
  194. J. D. Robertson, J. Chandra, V. Gogvadze, and S. Orrenius, “Biological reactive intermediates and mechanisms of cell death,” Advances in Experimental Medicine and Biology, vol. 500, pp. 1–10, 2001. View at: Google Scholar
  195. A. M. Gorman, B. Heavey, E. Creagh, T. G. Cotter, and A. Samali, “Antioxidant-mediated inhibition of the heat shock response leads to apoptosis,” FEBS Letters, vol. 445, no. 1, pp. 98–102, 1999. View at: Publisher Site | Google Scholar
  196. A. M. Gorman, E. Szegezdi, D. J. Quigney, and A. Samali, “Hsp27 inhibits 6-hydroxydopamine-induced cytochrome c release and apoptosis in PC12 cells,” Biochemical & Biophysical Research Communications, vol. 327, no. 3, pp. 801–810, 2005. View at: Publisher Site | Google Scholar
  197. W. R. Swindell, M. Huebner, and A. P. Weber, “Transcriptional profiling of arabidopsis heat shock proteins and transcription factors reveals extensive overlap between heat and non-heat stress response pathways,” BMC Genomics, vol. 8, article 125, 2007. View at: Publisher Site | Google Scholar
  198. S. B. Cullinan and J. A. Diehl, “Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway,” International Journal of Biochemistry & Cell Biology, vol. 38, no. 3, pp. 317–332, 2006. View at: Publisher Site | Google Scholar
  199. S. B. Cullinan and J. A. Diehl, “PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress,” Journal of Biological Chemistry, vol. 279, no. 19, pp. 20108–20117, 2004. View at: Publisher Site | Google Scholar
  200. Y. Chen, M. B. Azad, and S. B. Gibson, “Superoxide is the major reactive oxygen species regulating autophagy,” Cell Death and Differentiation, vol. 16, no. 7, pp. 1040–1052, 2009. View at: Publisher Site | Google Scholar
  201. A. Gorman, A. McGowan, and T. G. Cotter, “Role of peroxide and superoxide anion during tumour cell apoptosis,” FEBS Letters, vol. 404, no. 1, pp. 27–33, 1997. View at: Publisher Site | Google Scholar
  202. M. Meyer, R. Schreck, and P. A. Baeuerle, “H2O2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor,” EMBO Journal, vol. 12, no. 5, pp. 2005–2015, 1993. View at: Google Scholar
  203. T. L. Denning, H. Takaishi, S. E. Crowe, I. Boldogh, A. Jevnikar, and P. B. Ernst, “Oxidative stress induces the expression of Fas and Fas ligand and apoptosis in murine intestinal epithelial cells,” Free Radical Biology & Medicine, vol. 33, no. 12, pp. 1641–1650, 2002. View at: Publisher Site | Google Scholar
  204. H. Hug, S. Strand, A. Grambihler et al., “Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells,” Journal of Biological Chemistry, vol. 272, no. 45, pp. 28191–28193, 1997. View at: Publisher Site | Google Scholar
  205. K. Dobashi, K. Pahan, A. Chahal, and I. Singh, “Modulation of endogenous antioxidant enzymes by nitric oxide in rat C6 glial cells,” Journal of Neurochemistry, vol. 68, no. 5, pp. 1896–1903, 1997. View at: Google Scholar
  206. M. Asahi, J. Fujii, K. Suzuki et al., “Inactivation of glutathione peroxidase by nitric oxide. Implication for cytotoxicity,” Journal of Biological Chemistry, vol. 270, no. 36, pp. 21035–21039, 1995. View at: Publisher Site | Google Scholar
  207. L. Bosca and S. Hortelano, “Mechanisms of nitric oxide-dependent apoptosis: involvement of mitochondrial mediators,” Cellular Signalling, vol. 11, no. 4, pp. 239–244, 1999. View at: Publisher Site | Google Scholar
  208. Z. X. Chen and S. Pervaiz, “BCL-2: pro-or anti-oxidant?” Frontiers in Bioscience, vol. 1, pp. 263–268, 2009. View at: Google Scholar
  209. N. Mirkovic, D. W. Voehringer, M. D. Story, D. J. McConkey, T. J. McDonnell, and R. E. Meyn, “Resistance to radiation-induced apoptosis in bcl-2-expressing cells is reversed by depleting cellular thiols,” Oncogene, vol. 15, no. 12, pp. 1461–1470, 1997. View at: Google Scholar
  210. N. M. Robertson, J. Zangrilli, T. Fernandes-Alnemri, P. D. Friesen, G. Litwack, and E. S. Alnemri, “Baculovirus P35 inhibits the glucocorticoid-mediated pathway of cell death,” Cancer Research, vol. 57, no. 1, pp. 43–47, 1997. View at: Google Scholar
  211. N. K. Sah, T. K. Taneja, N. Pathak, R. Begum, M. Athar, and S. E. Hasnain, “The baculovirus antiapoptotic p35 gene also functions via an oxidant-dependent pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 9, pp. 4838–4843, 1999. View at: Google Scholar
  212. E. S. Alnemri, D. J. Livingston, D. W. Nicholson et al., “Human ICE/CED-3 protease nomenclature,” Cell, vol. 87, no. 2, p. 171, 1996. View at: Google Scholar
  213. J. Chandra, A. Samali, and S. Orrenius, “Triggering and modulation of apoptosis by oxidative stress,” Free Radical Biology & Medicine, vol. 29, no. 3-4, pp. 323–333, 2000. View at: Publisher Site | Google Scholar
  214. G. Melino, F. Bernassola, R. A. Knight, M. T. Corasaniti, G. Nistico, and A. Finazzi-Agro, “S-nitrosylation regulates apoptosis,” Nature, vol. 388, no. 6641, pp. 432–433, 1997. View at: Publisher Site | Google Scholar
  215. M. Leist, B. Single, H. Naumann et al., “Inhibition of mitochondrial ATP generation by nitric oxide switches apoptosis to necrosis,” Experimental Cell Research, vol. 249, no. 2, pp. 396–403, 1999. View at: Publisher Site | Google Scholar
  216. Y. Tsujimoto, S. Shimizu, Y. Eguchi, W. Kamiike, and H. Matsuda, “BCL-2 and Bcl-xL block apoptosis as well as necrosis: possible involvement of common mediators in apoptotic and necrotic signal transduction pathways,” Leukemia, vol. 11, supplement 3, pp. 380–382, 1997. View at: Google Scholar
  217. M. C. Maiuri, E. Zalckvar, A. Kimchi, and G. Kroemer, “Self-eating and self-killing: crosstalk between autophagy and apoptosis,” Nature Reviews Molecular Cell Biology, vol. 8, no. 9, pp. 741–752, 2007. View at: Publisher Site | Google Scholar
  218. B. Kalmar and L. Greensmith, “Activation of the heat shock response in a primary cellular model of motoneuron neurodegeneration-evidence for neuroprotective and neurotoxic effects,” Cellular & Molecular Biology Letters, vol. 14, no. 2, pp. 319–335, 2009. View at: Publisher Site | Google Scholar
  219. J. H. Lin, H. Li, D. Yasumura et al., “IRE1 signaling affects cell fate during the unfolded protein response,” Science, vol. 318, no. 5852, pp. 944–949, 2007. View at: Publisher Site | Google Scholar
  220. A. Jorns, A. Gunther, H.-J. Hedrich, D. Wedekind, M. Tiedge, and S. Lenzen, “Immune cell infiltration, cytokine expression, and β -cell apoptosis during the development of type 1 diabetes in the spontaneously diabetic LEW.1AR1/Ztm-iddm rat,” Diabetes, vol. 54, no. 7, pp. 2041–2052, 2005. View at: Publisher Site | Google Scholar
  221. D. L. Eizirik and T. Mandrup-Poulsen, “A choice of death—the signal-transduction of immune-mediated beta-cell apoptosis,” Diabetologia, vol. 44, no. 12, pp. 2115–2133, 2001. View at: Publisher Site | Google Scholar
  222. K. L. A. Souza, E. Gurgul-Convey, M. Elsner, and S. Lenzen, “Interaction between pro-inflammatory and anti-inflammatory cytokines in insulin-producing cells,” Journal of Endocrinology, vol. 197, no. 1, pp. 139–150, 2008. View at: Publisher Site | Google Scholar
  223. P. Pirot, D. L. Eizirik, and A. K. Cardozo, “Interferon- γ potentiates endoplasmic reticulum stress-induced death by reducing pancreatic beta cell defence mechanisms,” Diabetologia, vol. 49, no. 6, pp. 1229–1236, 2006. View at: Publisher Site | Google Scholar
  224. S. Lortz, E. Gurgul-Convey, S. Lenzen, and M. Tiedge, “Importance of mitochondrial superoxide dismutase expression in insulin-producing cells for the toxicity of reactive oxygen species and proinflammatory cytokines,” Diabetologia, vol. 48, no. 8, pp. 1541–1548, 2005. View at: Publisher Site | Google Scholar
  225. A. K. Azevedo-Martins, S. Lortz, S. Lenzen, R. Curi, D. L. Eizirik, and M. Tiedge, “Improvement of the mitochondrial antioxidant defense status prevents cytokine-induced nuclear factor- κ B activation in insulin-producing cells,” Diabetes, vol. 52, no. 1, pp. 93–101, 2003. View at: Publisher Site | Google Scholar
  226. S. Lenzen, J. Drinkgern, and M. Tiedge, “Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues,” Free Radical Biology & Medicine, vol. 20, no. 3, pp. 463–466, 1996. View at: Publisher Site | Google Scholar
  227. M. Tiedge, S. Lortz, J. Drinkgern, and S. Lenzen, “Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells,” Diabetes, vol. 46, no. 11, pp. 1733–1742, 1997. View at: Google Scholar
  228. E. Gurgul, S. Lortz, M. Tiedge, A. Jorns, and S. Lenzen, “Mitochondrial catalase overexpression protects insulin-producing cells against toxicity of reactive oxygen species and proinflammatory cytokines,” Diabetes, vol. 53, no. 9, pp. 2271–2280, 2004. View at: Publisher Site | Google Scholar
  229. D. L. Eizirik, A. K. Cardozo, and M. Cnop, “The role for endoplasmic reticulum stress in diabetes mellitus,” Endocrine Reviews, vol. 29, no. 1, pp. 42–61, 2008. View at: Publisher Site | Google Scholar
  230. J. L. Evans, I. D. Goldfine, B. A. Maddux, and G. M. Grodsky, “Are oxidative stress-activated signaling pathways mediators of insulin resistance and β -cell dysfunction?” Diabetes, vol. 52, no. 1, pp. 1–8, 2003. View at: Publisher Site | Google Scholar
  231. E. Diakogiannaki, S. Dhayal, C. E. Childs, P. C. Calder, H. J. Welters, and N. G. Morgan, “Mechanisms involved in the cytotoxic and cytoprotective actions of saturated versus monounsaturated long-chain fatty acids in pancreatic β -cells,” Journal of Endocrinology, vol. 194, no. 2, pp. 283–291, 2007. View at: Publisher Site | Google Scholar
  232. R. Robertson, H. Zhou, T. Zhang, and J. S. Harmon, “Chronic oxidative stress as a mechanism for glucose toxicity of the beta cell in type 2 diabetes,” Cell Biochemistry & Biophysics, vol. 48, no. 2-3, pp. 139–146, 2007. View at: Publisher Site | Google Scholar
  233. M. Cnop, N. Welsh, J.-C. Jonas, A. Jorns, S. Lenzen, and D. L. Eizirik, “Mechanisms of pancreatic β -cell death in type 1 and type 2 diabetes: many differences, few similarities,” Diabetes, vol. 54, supplement 2, pp. S97–S107, 2005. View at: Publisher Site | Google Scholar
  234. A. Jorns, K. J. Rath, O. Bock, and S. Lenzen, “Beta cell death in hyperglycaemic Psammomys obesus is not cytokine-mediated,” Diabetologia, vol. 49, no. 11, pp. 2704–2712, 2006. View at: Publisher Site | Google Scholar
  235. I. Kharroubi, L. Ladriere, A. K. Cardozo, Z. Dogusan, M. Cnop, and D. L. Eizirik, “Free fatty acids and cytokines induce pancreatic β -cell apoptosis by different mechanisms: role of nuclear factor- κ B and endoplasmic reticulum stress,” Endocrinology, vol. 145, no. 11, pp. 5087–5096, 2004. View at: Publisher Site | Google Scholar
  236. F. M. Ashcroft, “ K ATP channels and insulin secretion: a key role in health and disease,” Biochemical Society Transactions, vol. 34, part 2, pp. 243–246, 2006. View at: Google Scholar
  237. M. C. Saleh, M. B. Wheeler, and C. B. Chan, “Uncoupling protein-2: evidence for its function as a metabolic regulator,” Diabetologia, vol. 45, no. 2, pp. 174–187, 2002. View at: Publisher Site | Google Scholar
  238. J. H. Moffitt, B. A. Fielding, R. Evershed, R. Berstan, J. M. Currie, and A. Clark, “Adverse physicochemical properties of tripalmitin in beta cells lead to morphological changes and lipotoxicity in vitro,” Diabetologia, vol. 48, no. 9, pp. 1819–1829, 2005. View at: Publisher Site | Google Scholar
  239. M. Delepine, M. Nicolino, T. Barrett, M. Golamaully, G. M. Lathrop, and C. Julier, “EIF2AK3, encoding translation initiation factor 2- α kinase 3, is mutated in patients with Wolcott-Rallison syndrome,” Nature Genetics, vol. 25, no. 4, pp. 406–409, 2000. View at: Publisher Site | Google Scholar
  240. H. P. Harding, H. Zeng, Y. Zhang et al., “Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival,” Molecular Cell, vol. 7, no. 6, pp. 1153–1163, 2001. View at: Publisher Site | Google Scholar
  241. J. Wang, T. Takeuchi, S. Tanaka et al., “A mutation in the insulin 2 gene induces diabetes with severe pancreatic ß -cell dysfunction in the Mody mouse,” Journal of Clinical Investigation, vol. 103, no. 1, pp. 27–37, 1999. View at: Google Scholar
  242. S. Oyadomari, A. Koizumi, K. Takeda et al., “Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes,” Journal of Clinical Investigation, vol. 109, no. 4, pp. 525–532, 2002. View at: Publisher Site | Google Scholar
  243. W. C. Ladiges, S. E. Knoblaugh, J. F. Morton et al., “Pancreatic ß -cell failure and diabetes in mice with a deletion mutation of the endoplasmic reticulum molecular chaperone gene P58IPK,” Diabetes, vol. 54, no. 4, pp. 1074–1081, 2005. View at: Publisher Site | Google Scholar
  244. P. Kovacs, X. Yang, P. A. Permana, C. Bogardus, and L. J. Baier, “Polymorphisms in the oxygen-regulated protein 150 gene (ORP150) are associated with insulin resistance in Pima Indians,” Diabetes, vol. 51, no. 5, pp. 1618–1621, 2002. View at: Google Scholar
  245. K. Ozawa, M. Miyazaki, M. Matsuhisa et al., “The endoplasmic reticuluin chaperone improves insulin resistance in type 2 diabetes,” Diabetes, vol. 54, no. 3, pp. 657–663, 2005. View at: Publisher Site | Google Scholar
  246. U. Ozcan, E. Yilmaz, L. Ozcan et al., “Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes,” Science, vol. 313, no. 5790, pp. 1137–1140, 2006. View at: Publisher Site | Google Scholar
  247. S. Gandhi and N. W. Wood, “Molecular pathogenesis of Parkinson's disease,” Human Molecular Genetics, vol. 14, no. 18, pp. 2749–2755, 2005. View at: Publisher Site | Google Scholar
  248. S. Przedborski, “Pathogenesis of nigral cell death in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 11, supplement 1, pp. S3–S7, 2005. View at: Publisher Site | Google Scholar
  249. D. Sulzer, “Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease,” Trends in Neurosciences, vol. 30, no. 5, pp. 244–250, 2007. View at: Publisher Site | Google Scholar
  250. K. Steece-Collier, E. Maries, and J. H. Kordower, “Etiology of Parkinson's disease: genetics and environment revisited,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 22, pp. 13972–13974, 2002. View at: Publisher Site | Google Scholar
  251. J. M. Hatcher, K. D. Pennell, and G. W. Miller, “Parkinson's disease and pesticides: a toxicological perspective,” Trends in Pharmacological Sciences, vol. 29, no. 6, pp. 322–329, 2008. View at: Publisher Site | Google Scholar
  252. H. Mochizuki, “Gene therapy for Parkinson's disease,” Expert Review of Neurotherapeutics, vol. 7, no. 8, pp. 957–960, 2007. View at: Publisher Site | Google Scholar
  253. M. J. Farrer, “Genetics of Parkinson's disease: paradigm shifts and future prospects,” Nature Reviews Genetics, vol. 7, no. 4, pp. 306–318, 2006. View at: Publisher Site | Google Scholar
  254. M. W. Dodson and M. Guo, “Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease,” Current Opinion in Neurobiology, vol. 17, no. 3, pp. 331–337, 2007. View at: Publisher Site | Google Scholar
  255. R. Banerjee, A. A. Starkov, M. F. Beal, and B. Thomas, “Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis,” Biochimica et Biophysica Acta, vol. 1792, no. 7, pp. 651–663, 2009. View at: Publisher Site | Google Scholar
  256. J. L. St Martin, J. Klucken, T. F. Outeiro et al., “Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra,” Journal of Neurochemistry, vol. 100, no. 6, pp. 1449–1457, 2007. View at: Publisher Site | Google Scholar
  257. J. Klucken, Y. Shin, E. Masliah, B. T. Hyman, and P. J. McLean, “Hsp70 reduces α -synuclein aggregation and toxicity,” Journal of Biological Chemistry, vol. 279, no. 24, pp. 25497–25502, 2004. View at: Publisher Site | Google Scholar
  258. P. F. Durrenberger, M. D. Filiou, L. B. Moran et al., “DnaJB6 is present in the core of Lewy bodies and is highly up-regulated in Parkinsonian astrocytes,” Journal of Neuroscience Research, vol. 87, no. 1, pp. 238–245, 2009. View at: Publisher Site | Google Scholar
  259. J. Fargnoli, T. Kunisada, A. J. Fornace Jr., E. L. Schneider, and N. J. Holbrook, “Decreased expression of heat shock protein 70 mRNA and protein after heat treatment in cells of aged rats,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 2, pp. 846–850, 1990. View at: Google Scholar
  260. J. J. M. Hoozemans, E. S. van Haastert, P. Eikelenboom, R. A. I. de Vos, J. M. Rozemuller, and W. Scheper, “Activation of the unfolded protein response in Parkinson's disease,” Biochemical & Biophysical Research Communications, vol. 354, no. 3, pp. 707–711, 2007. View at: Publisher Site | Google Scholar
  261. W. A. Holtz and K. L. O'Malley, “Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons,” Journal of Biological Chemistry, vol. 278, no. 21, pp. 19367–19377, 2003. View at: Publisher Site | Google Scholar
  262. E. J. Ryu, H. P. Harding, J. M. Angelastro, O. V. Vitolo, D. Ron, and L. A. Greene, “Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease,” Journal of Neuroscience, vol. 22, no. 24, pp. 10690–10698, 2002. View at: Google Scholar
  263. R. M. Silva, V. Ries, T. F. Oo et al., “CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism,” Journal of Neurochemistry, vol. 95, no. 4, pp. 974–986, 2005. View at: Publisher Site | Google Scholar
  264. S. A. Fisher, B. L. Langille, and D. Srivastava, “Apoptosis during cardiovascular development,” Circulation Research, vol. 87, no. 10, pp. 856–864, 2000. View at: Google Scholar
  265. T. N. James, “Normal and abnormal consequences of apoptosis in the human heart: from postnatal morphogenesis to paroxysmal arrhythmias,” Circulation, vol. 90, no. 1, pp. 556–573, 1994. View at: Google Scholar
  266. C. Gill, R. Mestril, and A. Samali, “Losing heart: the role of apoptosis in heart disease—a novel therapeutic target?” FASEB Journal, vol. 16, no. 2, pp. 135–146, 2002. View at: Publisher Site | Google Scholar
  267. A. B. Gustafsson and R. A. Gottlieb, “Mechanisms of apoptosis in the heart,” Journal of Clinical Immunology, vol. 23, no. 6, pp. 447–459, 2003. View at: Publisher Site | Google Scholar
  268. H. Fliss and D. Gattinger, “Apoptosis in ischemic and reperfused rat myocardium,” Circulation Research, vol. 79, no. 5, pp. 949–956, 1996. View at: Google Scholar
  269. R. A. Gottlieb, K. O. Burleson, R. A. Kloner, B. M. Babior, and R. L. Engler, “Reperfusion injury induces apoptosis in rabbit cardiomyocytes,” Journal of Clinical Investigation, vol. 94, no. 4, pp. 1621–1628, 1994. View at: Google Scholar
  270. J. Misao, Y. Hayakawa, M. Ohno, S. Kato, T. Fujiwara, and H. Fujiwara, “Expression of bcl-2 protein, an inhibitor of apoptosis, and Bax, an accelerator of apoptosis, in ventricular myocytes of human hearts with myocardial infarction,” Circulation, vol. 94, no. 7, pp. 1506–1512, 1996. View at: Google Scholar
  271. J. Narula, N. Haider, R. Virmani et al., “Apoptosis in myocytes in end-stage heart failure,” New England Journal of Medicine, vol. 335, no. 16, pp. 1182–1189, 1996. View at: Publisher Site | Google Scholar
  272. G. Olivetti, R. Abbi, F. Quaini et al., “Apoptosis in the failing human heart,” New England Journal of Medicine, vol. 336, no. 16, pp. 1131–1141, 1997. View at: Publisher Site | Google Scholar
  273. G. Olivetti, F. Quaini, R. Sala et al., “Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart,” Journal of Molecular & Cellular Cardiology, vol. 28, no. 9, pp. 2005–2016, 1996. View at: Publisher Site | Google Scholar
  274. A. Saraste, K. Pulkki, M. Kallajoki, K. Henriksen, M. Parvinen, and L.-M. Voipio-Pulkki, “Apoptosis in human acute myocardial infarction,” Circulation, vol. 95, no. 2, pp. 320–323, 1997. View at: Google Scholar
  275. S. A. Cook, P. H. Sugden, and A. Clerk, “Regulation of bcl-2 family proteins during development and in response to oxidative stress in cardiac myocytes association with changes in mitochondrial membrane potential,” Circulation Research, vol. 85, no. 10, pp. 940–949, 1999. View at: Google Scholar
  276. R. von Harsdorf, P.-F. Li, and R. Dietz, “Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis,” Circulation, vol. 99, no. 22, pp. 2934–2941, 1999. View at: Google Scholar
  277. M. Neuss, R. Monticone, M. S. Lundberg, A. T. Chesley, E. Fleck, and M. T. Crow, “The apoptotic regulatory protein ARC (apoptosis repressor with caspase recruitment domain) prevents oxidant stress-mediated cell death by preserving mitochondrial function,” Journal of Biological Chemistry, vol. 276, no. 36, pp. 33915–33922, 2001. View at: Publisher Site | Google Scholar
  278. C. Fleury, B. Mignotte, and J.-L. Vayssiere, “Mitochondrial reactive oxygen species in cell death signaling,” Biochimie, vol. 84, no. 2-3, pp. 131–141, 2002. View at: Publisher Site | Google Scholar
  279. J. McMurray, J. McLay, M. Chopra, A. Bridges, and J. J. F. Belch, “Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease,” American Journal of Cardiology, vol. 65, no. 18, pp. 1261–1262, 1990. View at: Publisher Site | Google Scholar
  280. N. Singh and S. Aggarwal, “The effect of active oxygen generated by xanthine/xanthine oxidase on genes and signal transduction in mouse epidermal JB6 cells,” International Journal of Cancer, vol. 62, no. 1, pp. 107–114, 1995. View at: Publisher Site | Google Scholar
  281. J. L. Zweier, J. T. Flaherty, and M. L. Weisfeldt, “Direct measurement of free radical generation following reperfusion of ischemic myocardium,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 5, pp. 1404–1407, 1987. View at: Google Scholar
  282. S. E. Logue, A. B. Gustafsson, A. Samali, and R. A. Gottlieb, “Ischemia/reperfusion injury at the intersection with cell death,” Journal of Molecular & Cellular Cardiology, vol. 38, no. 1, pp. 21–33, 2005. View at: Publisher Site | Google Scholar
  283. K. Suzuki, Y. Sawa, Y. Kaneda, H. Ichikawa, R. Shirakura, and H. Matsuda, “In vivo gene transfection with heat shock protein 70 enhances myocardial tolerance to ischemia-reperfusion injury in rat,” Journal of Clinical Investigation, vol. 99, no. 7, pp. 1645–1650, 1997. View at: Google Scholar
  284. A. N. Aleshin, Y. Sawa, S. Kitagawa-Sakakida et al., “150-kDa oxygen-regulated protein attenuates myocardial ischemia-reperfusion injury in rat heart,” Journal of Molecular & Cellular Cardiology, vol. 38, no. 3, pp. 517–525, 2005. View at: Publisher Site | Google Scholar
  285. C.-Y. Li, J.-S. Lee, Y.-G. Ko, J.-I. Kim, and J.-S. Seo, “Heat shock protein 70 inhibits apoptosis downstream of cytochrome c release and upstream of caspase-3 activation,” Journal of Biological Chemistry, vol. 275, no. 33, pp. 25665–25671, 2000. View at: Publisher Site | Google Scholar
  286. M. A. H. Talukder, A. Kalyanasundaram, X. Zhao et al., “Expression of SERCA isoform with faster Ca 2 + transport properties improves postischemic cardiac function and Ca 2 + handling and decreases myocardial infarction,” American Journal of Physiology, vol. 293, no. 4, pp. H2418–H2428, 2007. View at: Publisher Site | Google Scholar
  287. S. W. Lowe and A. W. Lin, “Apoptosis in cancer,” Carcinogenesis, vol. 21, no. 3, pp. 485–495, 2000. View at: Google Scholar
  288. D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000. View at: Google Scholar
  289. S. W. Lowe, E. Cepero, and G. Evan, “Intrinsic tumour suppression,” Nature, vol. 432, no. 7015, pp. 307–315, 2004. View at: Publisher Site | Google Scholar
  290. R. W. Johnstone, A. A. Ruefli, and S. W. Lowe, “Apoptosis: a link between cancer genetics and chemotherapy,” Cell, vol. 108, no. 2, pp. 153–164, 2002. View at: Publisher Site | Google Scholar
  291. S. Fulda and K.-M. Debatin, “Targeting apoptosis pathways in cancer therapy,” Current Cancer Drug Targets, vol. 4, no. 7, pp. 569–576, 2004. View at: Publisher Site | Google Scholar
  292. G. Makin and C. Dive, “Apoptosis and cancer chemotherapy,” Trends in Cell Biology, vol. 11, no. 11, pp. S22–S26, 2001. View at: Publisher Site | Google Scholar
  293. C. Friesen, S. Fulda, and K.-M. Debatin, “Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells,” Leukemia, vol. 11, no. 11, pp. 1833–1841, 1997. View at: Google Scholar
  294. S. Fulda, M. Los, C. Friesen, and K.-M. Debatin, “Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system,” International Journal of Cancer, vol. 76, no. 1, pp. 105–114, 1998. View at: Publisher Site | Google Scholar
  295. T. Maeda, Y. Yamada, R. Moriuchi et al., “Fas gene mutation in the progression of adult T cell leukemia,” Journal of Experimental Medicine, vol. 189, no. 7, pp. 1063–1071, 1999. View at: Publisher Site | Google Scholar
  296. T. H. Landowski, N. Qu, I. Buyuksal, J. S. Painter, and W. S. Dalton, “Mutations in the Fas antigen in patients with multiple myeloma,” Blood, vol. 90, no. 11, pp. 4266–4270, 1997. View at: Google Scholar
  297. K. Gronbaek, P. T. Straten, E. Ralfkiaer et al., “Somatic fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity,” Blood, vol. 92, no. 9, pp. 3018–3024, 1998. View at: Google Scholar
  298. S. H. Lee, M. S. Shin, W. S. Park et al., “Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer,” Oncogene, vol. 18, no. 25, pp. 3754–3760, 1999. View at: Publisher Site | Google Scholar
  299. S. H. Lee, M. S. Shin, W. S. Park et al., “Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder,” Cancer Research, vol. 59, no. 13, pp. 3068–3072, 1999. View at: Google Scholar
  300. W. S. Park, R. R. Oh, Y. S. Kim et al., “Somatic mutations in the death domain of the Fas (Apo-I/CD95) gene in gastric cancer,” Journal of Pathology, vol. 193, no. 2, pp. 162–168, 2001. View at: Publisher Site | Google Scholar
  301. I. I. Wistuba, C. Behrens, A. K. Virmani et al., “Allelic losses at chromosome 8p21–23 are early and frequent events in the pathogenesis of lung cancer,” Cancer Research, vol. 59, no. 8, pp. 1973–1979, 1999. View at: Google Scholar
  302. M. Emi, Y. Fujiwara, T. Nakajima et al., “Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer,” Cancer Research, vol. 52, no. 19, pp. 5368–5372, 1992. View at: Google Scholar
  303. O. Micheau, “Cellular FLICE-inhibitory protein: an attractive therapeutic target?” Expert Opinion on Therapeutic Targets, vol. 7, no. 4, pp. 559–573, 2003. View at: Publisher Site | Google Scholar
  304. A. M. Hunter, E. C. LaCasse, and R. G. Korneluk, “The inhibitors of apoptosis (IAPs) as cancer targets,” Apoptosis, vol. 12, no. 9, pp. 1543–1568, 2007. View at: Publisher Site | Google Scholar
  305. S. Fulda, “Caspase-8 in cancer biology and therapy,” Cancer Letters, vol. 281, no. 2, pp. 128–133, 2009. View at: Publisher Site | Google Scholar
  306. S. Kitada, I. M. Pedersen, A. D. Schimmer, and J. C. Reed, “Dysregulation of apoptosis genes in hematopoietic malignancies,” Oncogene, vol. 21, no. 21, pp. 3459–3474, 2002. View at: Publisher Site | Google Scholar
  307. N. Rampino, H. Yamamoto, Y. Ionov et al., “Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype,” Science, vol. 275, no. 5302, pp. 967–969, 1997. View at: Publisher Site | Google Scholar
  308. S. S. Zinkel, C. C. Ong, D. O. Ferguson et al., “Proapoptotic BID is required for myeloid homeostasis and tumor suppression,” Genes and Development, vol. 17, no. 2, pp. 229–239, 2003. View at: Publisher Site | Google Scholar
  309. H. Tagawa, S. Karnan, R. Suzuki et al., “Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM,” Oncogene, vol. 24, no. 8, pp. 1348–1358, 2005. View at: Publisher Site | Google Scholar
  310. C. Mestre-Escorihuela, F. Rubio-Moscardo, J. A. Richter et al., “Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas,” Blood, vol. 109, no. 1, pp. 271–280, 2007. View at: Publisher Site | Google Scholar
  311. D. R. Fels and C. Koumenis, “The PERK/eIF2 α /ATF4 module of the UPR in hypoxia resistance and tumor growth,” Cancer Biology & Therapy, vol. 5, no. 7, pp. 723–728, 2006. View at: Google Scholar
  312. C. Koumenis and B. G. Wouters, ““Translating” tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways,” Molecular Cancer Research, vol. 4, no. 7, pp. 423–436, 2006. View at: Publisher Site | Google Scholar
  313. H.-C. Zheng, H. Takahashi, X.-H. Li et al., “Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas,” Human Pathology, vol. 39, no. 7, pp. 1042–1049, 2008. View at: Publisher Site | Google Scholar
  314. P. Pyrko, A. H. Schonthal, F. M. Hofman, T. C. Chen, and A. S. Lee, “The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas,” Cancer Research, vol. 67, no. 20, pp. 9809–9816, 2007. View at: Publisher Site | Google Scholar
  315. A. C. Koong, V. Chauhan, and L. Romero-Ramirez, “Targeting XBP-1 as a novel anti-cancer strategy,” Cancer Biology & Therapy, vol. 5, no. 7, pp. 756–759, 2006. View at: Google Scholar
  316. S. Qin and P. B. Chock, “Implication of phosphatidylinositol 3-kinase membrane recruitment in hydrogen peroxide-induced activation of PI3K and Akt,” Biochemistry, vol. 42, no. 10, pp. 2995–3003, 2003. View at: Publisher Site | Google Scholar
  317. S. Pervaiz, J. Cao, O. S. P. Chao, Y. Y. Chin, and M.-V. Clement, “Activation of the RacGTPase inhibits apoptosis in human tumor cells,” Oncogene, vol. 20, no. 43, pp. 6263–6268, 2001. View at: Publisher Site | Google Scholar
  318. D. Mahalingam, R. Swords, J. S. Carew, S. T. Nawrocki, K. Bhalla, and F. J. Giles, “Targeting HSP90 for cancer therapy,” British Journal of Cancer, vol. 100, no. 10, pp. 1523–1529, 2009. View at: Publisher Site | Google Scholar
  319. C. Garrido, M. Brunet, C. Didelot, Y. Zermati, E. Schmitt, and G. Kroemer, “Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties,” Cell Cycle, vol. 5, no. 22, pp. 2592–2601, 2006. View at: Google Scholar


Copyright © 2010 Simone Fulda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Properties of heat shock proteins (HSPs) and heat shock factor (HSF)

Heat shock factors: integrators of cell stress, development and lifespan

Heat shock factors (HSFs) are essential for all organisms to survive exposures to acute stress. They are best known as inducible transcriptional regulators of genes encoding molecular chaperones and other stress proteins. Four members of the HSF family are also important for normal development and lifespan-enhancing pathways, and the repertoire of HSF targets has thus expanded well beyond the heat shock genes. These unexpected observations have uncovered complex layers of post-translational regulation of HSFs that integrate the metabolic state of the cell with stress biology, and in doing so control fundamental aspects of the health of the proteome and ageing.

In the early 1960s, Ritossa made the seminal discovery of temperature-induced puffs in polytene chromosomes of Drosophila melanogaster larvae salivary glands 1 . A decade later, it was shown that the puffing pattern corresponded to a robust activation of genes encoding the heat shock proteins (HSPs), which function as molecular chaperones 2 . The heat shock response is a highly conserved mechanism in all organisms from yeast to humans that is induced by extreme proteotoxic insults such as heat, oxidative stress, heavy metals, toxins and bacterial infections. The conservation among different eukaryotes suggests that the heat shock response is essential for survival in a stressful environment.

The heat shock response is mediated at the transcriptional level by cis-acting sequences called heat shock elements (HSEs BOX 1) that are present in multiple copies upstream of the HSP genes 3 . The first evidence for a specific transcriptional regulator, the heat shock factor (HSF) that can bind to the HSEs and induce HSP gene expression, was obtained through DNA–protein interaction studies on nuclei isolated from D. melanogaster cells 4,5 . Subsequent studies showed that, in contrast to a single HSF in invertebrates, multiple HSFs are expressed in plants and vertebrates 6–8 . The mammalian HSF family consists of four members: HSF1,HSF2, HSF3 and HSF4. Distinct HSFs possess unique and overlapping functions (FIG. 1), exhibit tissue-specific patterns of expression and have multiple post-translational modifications (PTMs) and interacting protein partners 7,9,10 . Functional crosstalk between HSF family members and PTMs facilitates the fine-tuning of HSF-mediated gene regulation. The identification of many targets has further extended the impact of HSFs beyond the heat shock response. Here, we present the recent discoveries of novel target genes and physiological functions of HSFs, which have changed the view that HSFs act solely in the heat shock response. Based on the current knowledge of small-molecule activators and inhibitors of HSFs, we also highlight the potential for pharmacologic modulation of HSF-mediated gene regulation.

The heat shock element

Heat shock factors (HSFs) act through a regulatory upstream promoter element, called the heat shock element (HSE). In the DNA-bound form of a HSF, each DNA-binding domain (DBD) recognizes the HSE in the major groove of the double helix 6 . The HSE was originally identified using S1 mapping of transcripts of the Drosophila melanogaster heat shock protein (HSP) genes 3 (see the figure part a). Residues –47 to –66 are necessary for heat inducibility. HSEs in HSP gene promoters are highly conserved and consist of inverted repeats of the pentameric sequence nGAAn 132 . The type of HSEs that can be found in the proximal promoter regions of HSP genes is composed of at least three contiguous inverted repeats: nTTCnnGAAnnTTCn 132–134 . The promoters of HSF target genes can also contain more than one HSE, thereby allowing the simultaneous binding of multiple HSFs. The binding of an HSF to an HSE occurs in a cooperative manner, whereby binding of an HSF trimer facilitates binding of the next one 135 . More recently, Trinklein and colleagues used chromatin immunoprecipitation to enrich sequences bound by HSF1 in heat-shocked human cells to define the HSE consensus sequence. They confirmed the original finding of Xiao and Lis, who identified guanines as the most conserved nucleotides in HSEs 87,133 (see the figure part b). Moreover, in a pair of inverted repeats, a TTC triplet 5′ of a GAA triplet is separated by a pyrimidine–purine dinucleotide, whereas the two nucleotides separating a GAA triplet 5′ from a TTC triplet is unconstrained 87 . The discovery of novel HSF target genes that are not involved in the heat shock response has rendered it possible that there may be HSEs in many genes other than the HSP genes. Although there are variations in these HSEs, the spacing and position of the guanines are invariable 7 . Therefore, both the nucleotides and the exact spacing of the repeated units are considered as key determinants for recognition by HSFs and transcriptional activation. Part b of the figure is modified, with permission, from REF. 87 © (2004) The American Society for Cell Biology.

The mammalian HSF machinery

HSFs as stress integrators

A hallmark of stressed cells and organisms is the increased synthesis of HSPs, which function as molecular chaperones to prevent protein misfolding and aggregation to maintain protein homeostasis, also called proteostasis 11 . The transcriptional activation of HSP genes is mediated by HSFs (FIG. 2a), of which HSF1 is the master regulator in vertebrates. Hsf1-knockout mouse and cell models have revealed that HSF1 is a prerequisite for the transactivation of HSP genes, maintenance of cellular integrity during stress and development of thermotolerance 12–15 . HSF1 is constitutively expressed in most tissues and cell types 16 , where it is kept inactive in the absence of stress stimuli. Thus, the DNA-binding and transactivation capacity of HSF1 are coordinately regulated through multiple PTMs, protein–protein interactions and subcellular localization. HSF1 also has an intrinsic stress-sensing capacity, as both D. melanogaster and mammalian HSF1 can be converted from a monomer to a homotrimer in vitro in response to thermal or oxidative stress 17–19 .

Members of the mammalian HSF family

Functional domains

HSFs, like other transcription factors, are composed of functional domains. These have been most thoroughly characterized for HSF1 and are schematically presented in FIG. 2b. The DNA-binding domain (DBD) is the best preserved domain in evolution and belongs to the family of winged helix-turn-helix DBDs 20–22 . The DBD forms a compact globular structure, except for a flexible wing or loop that is located between β-strands 3 and 4 (REF. 6 ). This loop generates a protein– protein interface between adjacent subunits of the HSF trimer that enhances high-affinity binding to DNA by cooperativity between different HSFs 23 . The DBD can also mediate interactions with other factors to modulate the transactivating capacity of HSFs 24 . Consequently, the DBD is considered as the signature domain of HSFs for target-gene recognition.

The trimerization of HSFs is mediated by arrays of hydrophobic heptad repeats (HR-A and HR-B) that form a coiled coil, which is characteristic for many Leu zippers 6,25 (FIG. 2b). The trimeric assembly is unusual, as Leu zippers typically facilitate the formation of homodimers or heterodimers. Suppression of spontaneous HSF trimerization is mediated by yet another hydrophobic repeat, HR-C 26–28 . Human HSF4 lacks the HR-C, which could explain its constitutive trimerization and DNA-binding activity 29 . Positioned at the extreme carboxyl terminus of HSFs is the transactivation domain, which is shared among all HSFs 6 except for yeast Hsf, which has transactivation domains in both the amino and C termini, and HSF4A, which completely lacks a transactivation domain 29–31 . In HSF1, the transactivation domain is composed of two modules — AD1 and AD2, which are rich in hydrophobic and acidic residues (FIG. 3a) — that together ensures a rapid and prolonged response to stress 32,33 . The transactivation domain was originally proposed to provide stress inducibility to HSF1 (REFS 34,35 ), but it soon became evident that an intact regulatory domain, located between the HR-A and HR-B and the transactivation domain, is essential for the responsiveness to stress stimuli 32,33,36,37 . Because several amino acids that are known targets for different PTMs reside in the regulatory domain 33,38–42 , the structure and function of this domain are under intensive investigation.

HSF1 undergoes multiple PTMs on activation

Regulation of the HSF1 activation–attenuation cycle

The conversion of the inactive monomeric HSF1 to high-affinity DNA-binding trimers is the initial step in the multistep activation process and is a common feature of all eukaryotic HSFs 43,44 (FIG. 3b). There is compelling evidence for HSF1 interacting with multiple HSPs at different phases of its activation cycle. For example, monomeric HSF1 interacts weakly with HSP90 and, on stress, HSF1 dissociates from the complex, allowing HSF1 trimerization 45,46 (FIG. 3b). Trimeric HSF1 can be kept inactive when its regulatory domain is bound by a multi-chaperone complex of HSP90, co-chaperone p23 (also known as PTGES3) and immunophilin FK506-binding protein 5 (FKBP52 also known as FKBP4) 46–51 . Elevated levels of both HSP90 and HSP70 negatively regulate HSF1 and prevent trimer formation on heat shock 52 . Activated HSF1 trimers also interact with HSP70 and the co-chaperone HSP40 (also known as DNAJB1), but instead of suppressing the DNA-binding activity of HSF1, this interaction inhibits its transactivation capacity 52–54 . Although the inhibitory mechanism is still unknown, the negative feedback from the end products of HSF1-dependent transcription (the HSPs) provides an important control step in adjusting the duration and intensity of HSF1 activation according to the levels of chaperones and presumably the levels of nascent and misfolded peptides.

A ribonucleoprotein complex containing eukaryotic elongation factor 1A (eEF1A) and a non-coding RNA, heat shock RNA-1 (HSR-1), has been reported to possess a thermosensing capacity. According to the proposed model, HSR-1 undergoes a conformational change in response to heat stress and together with eEF1A facilitates trimerization of HSF1 (REF. 55 ). How this activation mode relates to the other regulatory mechanisms associated with HSFs remains to be elucidated.

Throughout the activation–attenuation cycle, HSF1 undergoes extensive PTMs, including acetylation, phosphorylation and sumoylation (FIG. 3). HSF1 is also a phosphoprotein under non-stress conditions, and the results from mass spectrometry (MS) analyses combined with phosphopeptide mapping experiments indicate that at least 12 Ser residues are phosphorylated 41,56–59 . Among these sites, stress-inducible phosphorylation of Ser230 and Ser326 in the regulatory domain contributes to the transactivation function of HSF1 (REFS 38,41 ). Phosphorylation-mediated sumoylation on a single Lys residue in the regulatory domain occurs rapidly and transiently on exposure to heat shock Ser303 needs to be phosphorylated before a small ubiquitin-related modifier (SUMO) can be conjugated to Lys298 (REF. 39 ). The extended consensus sequence ΨKxExxSP has been named the phosphorylation-dependent sumoylation motif (PDSM FIG. 3) 40 . The PDSM was initially discovered in HSF1 and subsequently found in many other proteins, especially transcriptional regulators such as HSF4, GATA1, myocyte-specific enhancer factor 2A (MEF2A) and SP3, which are substrates for both SUMO conjugation and Pro-directed kinases 40,60–62 .

Recently, Mohideen and colleagues showed that a conserved basic patch on the surface of the SUMO-conjugating enzyme ubiquitin carrier protein 9 (UBC9 also known as UBE2I) discriminates between the phosphorylated and non-phosphorylated PDSM of HSF1 (REF. 63 ). Future studies will be directed at elucidating the molecular mechanisms for dynamic phosphorylation and UBC9-dependent SUMO conjugation in response to stress stimuli and establishing the roles of kinases, phosphatases and desumoylating enzymes in the heat shock response. The kinetics of phosphorylation-dependent sumoylation of HSF1 correlates inversely with the severity of heat stress, and, as the transactivation capacity of HSF1 is impaired by sumoylation and this PTM is removed when maximal HSF1 activity is required 40 , sumoylation could modulate HSF1 activity under moderate stress conditions. The mechanisms by which SUMO modification represses the transactivating capacity of HSF1, and the functional relationship of this PTM with other modifications that HSF1 is subjected to, will be investigated with endogenous substrate proteins.

Phosphorylation and sumoylation of HSF1 occur rapidly on heat shock, whereas the kinetics of acetylation are delayed and coincide with the attenuation phase of the HSF1 activation cycle. Stress-inducible acetylation of HSF1 is regulated by the balance of acetylation by p300–CBP (CREB-binding protein) and deacetylation by the NAD + -dependent sirtuin, SIRT1. Increased expression and activity of SIRT1 enhances and prolongs the DNA-binding activity of HSF1 at the human HSP70.1promoter, whereas downregulation of SIRT1 enhances the acetylation of HSF1 and the attenuation of DNA-binding without affecting the formation of HSF1 trimers 42 . This finding led to the discovery of a novel regulatory mechanism of HSF1 activity, whereby SIRT1 maintains HSF1 in a state that is competent for DNA binding by counteracting acetylation (FIG. 3). In the light of current knowledge, the attenuation phase of the HSF1 cycle is regulated by a dual mechanism: a dependency on the levels of HSPs that feed back directly by weak interactions with HSF1, and a parallel step that involves the SIRT1-dependent control of the DNA-binding activity of HSF1. Because SIRT1 has been implicated in caloric restriction and ageing, the age-dependent loss of SIRT1 and impaired HSF1 activity correlate with an impairment of the heat shock response and proteostasis in senescent cells, connecting the heat shock response to nutrition and ageing (see below).

HSF dynamics on the HSP70 promoter

For decades, the binding of HSF to the HSP70.1 gene has served as a model system for inducible transcription in eukaryotes. In D. melanogaster, HSF is constitutively nuclear and low levels of HSF are associated with the HSP70promoter before heat shock 64–66 . The uninduced HSP70 promoter is primed for transcription by a transcriptionally engaged paused RNA polymerase II (RNAP II) 67,68 . RNAP II pausing is greatly enhanced by nucleosome formation in vitro, implying that chromatin remodelling is crucial for the release of paused RNAP II 69 . It has been proposed that distinct hydrophobic residues in the transactivation domain of human HSF1 can stimulate RNAP II release and directly interact withBRG1, the ATPase subunit of the chromatin remodelling complex SWI/SNF 70,71 . Upon heat shock, RNAP II is released from its paused state, leading to the synthesis of a full-length transcript. Rapid disruption of nucleosomes occurs across the entire HSP70 gene, at a rate that is faster than RNAP II-mediated transcription 72 . The nucleosome displacement occurs simultaneously with HSF recruitment to the promoter in D. melanogaster. Downregulation of HSF abrogates the loss of nucleosomes, indicating that HSF provides a signal for chromatin rearrangement, which is required for HSP70 nucleosome displacement. Within seconds of heat shock, the amount of HSF at the promoter increases drastically and HSF translocates from the nucleoplasm to several native loci, including HSP genes. Interestingly, the levels of HSF occupying the HSP70 promoter reach saturation soon after just one minute 65,73 .

HSF recruits the co-activating mediator complex to the heat shock loci, which acts as a bridge to transmit activating signals from transcription factors to the basal transcription machinery. The mediator complex is recruited by a direct interaction with HSF: the transactivation domain of D. melanogaster HSF binds to TRAP80(also known as MED17), a subunit of the mediator complex 74 . HSF probably has other macromolecular contacts with the preinitiation complex as it binds to TATA-binding protein (TBP) and the general transcription factor TFIIB in vitro 75,76 . In contrast to the rapid recruitment and elongation of RNAP II on heat shock, activated HSF exchanges very slowly at the HSP70 promoter. HSF stays stably bound to DNA in vivo and no turnover or disassembly of transcription activator is required for successive rounds of HSP70 transcription 65,68 .

Functional interplay between HSFs

Although HSF1 is the principal regulator of the heat shock response, HSF2 also binds to the promoters of HSP genes. In light of our current knowledge, HSF2 strictly depends on HSF1 for its stress-related functions as it is recruited to HSP gene promoters only in the presence of HSF1 and this cooperation requires an intact HSF1 DBD 77 . Nevertheless, HSF2 modulates, both positively and negatively, the HSF1-mediated inducible expression of HSP genes, indicating that HSF2 can actively participate in the transcriptional regulation of the heat shock response. Coincident with the stress-induced transcription of HSP genes, HSF1 and HSF2 colocalize and accumulate rapidly on stress into nuclear stress bodies (NSBs BOX 2), where they bind to a subclass of satellite III repeats, predominantly in the human chromosome 9q12 (REFS 78󈞼 ). Consequently, large and stable non-coding satellite III transcripts are synthesized in an HSF1-dependent manner in NSBs 81,82 . The function of these transcripts and their relationship with other HSF1 targets, and the heat shock response in general, remain to be elucidated.

Nuclear stress bodies

The cell nucleus is highly compartmentalized and dynamic. Many nuclear factors are diffusely distributed throughout the nucleoplasm, but they can also accumulate in distinct subnuclear compartments, such as nucleoli, speckles, Cajal bodies and promyelocytic leukaemia (PML) bodies 136 . Nuclear stress bodies (NSBs) are different from any other known nuclear bodies 137,138 . Although NSBs were initially thought to contain aggregates of denatured proteins and be markers of heat-shocked cells, their formation can be elicited by various stresses, such as heavy metals and proteasome inhibitors 137 . NSBs are large structures, 0.3–3 μm in diameter, and are usually located close to the nucleoli or nuclear envelope 137,138 . NSBs consist of two populations: small, brightly stained bodies and large, clustered and ring-like structures 137 .

NSBs appear transiently and are the main site of heat shock factor 1 (HSF1) and HSF2 accumulation in stressed human cells 80 . HSF1 and HSF2 form a physically interacting complex and colocalize into small and barely detectable NSBs after only five minutes of heat shock, but the intensity and size of NSBs increase after hours of continuous heat shock. HSF1 and HSF2 colocalize in HeLa cells that have been exposed to heat shock for one hour at 42°C (see the figure confocal microscopy image with HSF1–green fluorescent protein in green and endogenous HSF2 in red). NSBs form on specific chromosomal loci, mainly on q12 of human chromosome 9, where HSFs bind to a subclass of satellite III repeats 78,79,83 . Stress-inducible and HSF1-dependent transcription of satellite III repeats has been shown to produce non-coding RNA molecules, called satellite III transcripts 81,82 . The 9q12 locus consists of pericentromeric heterochromatin, and the satellite III repeats provide scaffolds for docking components, such as splicing factors and other RNA-processing proteins 139–143 .

HSF2 also modulates the heat shock response through the formation of heterotrimers with HSF1 in the NSBs when bound to the satellite III repeats 83 (FIG. 4). Studies on the functional significance of heterotrimerization indicate that HSF1 depletion prevents localization of HSF2 to NSBs and abolishes the stress-induced synthesis of satellite III transcripts. By contrast, increased expression of HSF2 leads to its own activation and the localization of both HSF1 and HSF2 to NSBs, where transcription is spontaneously induced in the absence of stress stimuli. These results suggest that HSF2 can incorporate HSF1 into a transcriptionally competent heterotrimer 83 . It is possible that the amounts of HSF2 available for heterotrimerization with HSF1 influence stress-inducible transcription, and that HSF1–HSF2 heterotrimers regulate transcription in a temporal manner. During the acute phase of heat shock, HSF1 is activated and HSF1–HSF2 heterotrimers are formed, whereas upon prolonged exposures to heat stress the levels of HSF2 are diminished, thereby limiting heterotrimerization 83 . Intriguingly, in specific developmental processes such as corticogenesis and spermatogenesis, the expression of HSF2 increases spatiotemporarily, leading to its spontaneous activation. Therefore, it has been proposed that HSF-mediated transactivation can be modulated by the levels of HSF2 to provide a switch that integrates the responses to stress and developmental stimuli 83 (FIG. 4). Functional relationships between different HSFs are emerging, and the synergy of DNA-binding activities among HSF family members offers an efficient way to control gene expression in a cell- and stimulus-specific manner to orchestrate the differential upstream signalling and target-gene networks.

Interactions between different HSFs provide distinct functional modes in transcriptional regulation

A new member of the mammalian HSF family, mouse HSF3, was recently identified 10 . Avian HSF3 was shown to be activated at higher temperatures and with different kinetics than HSF1 (REF. 84 ), whereas in mice, heat shock induces the nuclear translocation of HSF3 and activation of stress-responsive genes other than HSP genes 10 . Future experiments will determine whether HSF3 is capable of interacting with other HSFs, potentially through heterocomplex formation. HSF4 has not been implicated in the heat shock response, but it competes with HSF1 for common target genes in mouse lens epithelial cells 85 , which will be discussed below. It is important to elucidate whether the formation of homotrimers or hetero trimers between different family members is a common theme in HSF-mediated transcriptional regulation.

HSFs as developmental regulators

Evidence is accumulating that HSFs are highly versatile transcription factors that, in addition to protecting cells against proteotoxic stress, are vital for many physioogical functions, especially during development. The initial observations using deletion experiments of the D. melanogaster Hsf gene revealed defective oogenesis and larvae development 86 . These effects were not caused by obvious changes in HSP gene expression patterns, which is consistent with the subsequent studies showing that basal expression of HSP genes during mouse embryogenesis is not affected by the lack of HSF1 (REF. 13 ). These results are further supported by genome-wide gene expression studies revealing that numerous genes, not classified as HSP genes or molecular chaperones, are under HSF1-dependent control 87,88 .

Although mice lacking HSF1 can survive to adulthood, they exhibit multiple defects, such as increased prenatal lethality, growth retardation and female infertility 13 . Fertilized oocytes do not develop past the zygotic stage when HSF1-deficient female mice are mated with wild-type male mice, indicating that HSF1 is a maternal factor that is essential for early post-fertilization development 89 . Recently, it was shown that HSF1 is abundantly expressed in maturing oocytes, where it regulates specifically Hsp90α transcription 90 . The HSF1-deficient oocytes are devoid of HSP90α and exhibit a blockage of meiotic maturation, including delayed G2–M transition or germinal vesicle breakdown and defective asymmetrical division 90 . Moreover, intra-ovarian HSF1-depleted oocytes contain dysfunctional mitochondria and are sensitive to oxidative stress, leading to reduced survival 91 . The complex phenotype of Hsf1-knockout mice also demonstrates the involvement of HSF1 in placenta formation, placode development and the immune system 15,85,92,93 , further strengthening the evidence for a protective function of HSF1 in development and survival.

Both HSF1 and HSF2 are key regulators in the developing brain and in maintaining proteostasis in the central nervous system. Disruption of Hsf1 results in enlarged ventricles, accompanied by astrogliosis, neurodegeneration, progressive myelin loss and accumulation of ubiquitylated proteins in specific regions of the postnatal brain under non-stressed conditions 94,95 . The expression of HSP25 (also known as HSPB1) and α-crystallin B chain (CRYAB), which are known to protect cells against stress-induced protein damage and cell death, is dramatically decreased in brains lacking HSF1 (REF. 13 ). In contrast to HSF1, HSF2 is already at peak levels during early brain development in mice and is predominantly expressed in the proliferative neuronal progenitors of the ventricular zone and post-mitotic neurons of the cortical plate 96–99 . HSF2-deficient mice have enlarged ventricles and defects in cortical lamination owing to abnormal neuronal migration 97–99 . Incorrect positioning of superficial neurons during cortex formation in HSF2-deficient embryos is caused by decreased expression of the cyclin-dependent kinase 5 (CDK5) activator p35, which is a crucial regulator of the cortical migration signalling pathway 100,101 . The p35 gene was identified as the first direct target of HSF2 in cortex development 99 . As correct cortical migration requires the coordination of multiple signalling molecules, it is likely that HSF2, either directly or indirectly, also regulates other components of the same pathway.

Cooperativity of HSFs in development

In adult mice, HSF2 is most abundantly expressed in certain cell types of testes, specifically pachytene spermatocytes and round spermatids 102 . The cell-specific expression of HSF2 in testes is regulated by a microRNA, miR-18, that directly binds to the 3′ untranslated region (UTR) of HSF2 (J.K. Björk, A. Sandqvist, A.N. Elsing, N. Kotaja and L.S., unpublished observations). Targeting of HSF2 in spermatogenesis reveals the first physiological role for miR-18, which belongs to the oncomir-1 cluster associated mainly with tumour progression 103 . In accordance with the expression pattern during the maturation of male germ cells, HSF2-null male mice display several abnormal features in spermatogenesis, ranging from smaller testis size and increased apoptosis at the pachytene stage to a reduced amount of sperm and abnormal sperm head shape 97,98,104 . A genome-wide search for HSF2 target promoters in mouse testis revealed the occupancy of HSF2 on the sex chromosomal multi-copy genes spermiogenesis specific transcript on the Y 2 (Ssty2), Sycp3-like Y-linked (Sly) and Sycp3-like X-linked (Slx), which are important for sperm quality 104 . Compared with the Hsf2-knockout phenotype, disruption of both Hsf1 and Hsf2 results in a more pronounced phenotype, including larger vacuolar structures, more widely spread apoptosis and a complete lack of mature spermatozoa and male sterility 105 . The hypo thesis that the activities of HSF1 and HSF2 are intertwined and essential for spermatogenesis is further supported by our results that HSF1 and HSF2 synergistically regulate the sex chromosomal multi-copy genes in post-meiotic round spermatids (M.Å., A. Vihervaara, E.S. Christians, E. Henriksson and L.S., unpublished observations). Given that the sex chromatin mostly remains silent after meiosis, HSF1 and HSF2 are currently the only known transcriptional regulators during post-meiotic repression. These results, together with the earlier findings that HSF2 can also form heterotrimers with HSF1 in testes 83 , strongly suggest that HSF1 and HSF2 act in a heterocomplex and fine-tune transcription of their common target genes during the maturation of male germ cells.

HSF1 and HSF4 are required for the maintenance of sensory organs, especially when the organs are exposed to environmental stimuli for the first time after birth 85,88 . During the early postnatal period, Hsf1-knockout mice display severe atrophy of the olfactory epithelium, increased accumulation of mucus and death of olfactory sensory neurons 88 . Although lens development in HSF4-deficient mouse embryos is normal, severe abnormalities, including inclusion-like structures in lens fibre cells, appear soon after birth and the mice develop cataracts 85,106,107 . Intriguingly, inherited severe cataracts occurring in Chinese and Danish families have been associated with a mutation in the DBD of HSF4 (REF. 108 ). In addition to the established target genes, Hsp25, Hsp70 and Hsp90, several new targets for HSF1 and HSF4, such as crystallin γF (Crygf), fibroblast growth factor 7 (Fgf7) and leukaemia inhibitory factor (Lif) have been found to be crucial for sensory organs 85,88 . Furthermore, binding of either HSF1 or HSF4 to the Fgf7 promoter shows opposite effects on gene expression, suggesting competitive functions between the two family members 85 . In addition to the proximal promoters, HSF1, HSF2 and HSF4 bind to other genomic regions (that is, introns and distal parts of protein-coding genes in mouse lens), and there is also evidence for either synergistic interplay or competition between distinct HSFs occupying the target-gene promoters 109 . It is possible that the different HSFs are able to compensate for each other to some extent. Thus, the identification of novel functions and target genes for HSFs has been a considerable step forward in understanding their regulatory mechanisms in development.

HSFs and lifespan

The lifespan of an organism is directly linked to the health of its tissues, which is a consequence of the stability of the proteome and functionality of its molecular machineries. During its lifetime, an organism constantly encounters environmental and physiological stress and requires an efficient surveillance of protein quality to prevent the accumulation of protein damage and the disruption of proteostasis. Proteotoxic insults contribute to cellular ageing, and numerous pathophysiological conditions, associated with impaired protein quality control, increase prominently with age 11 . From studies on the molecular basis of ageing, in which a wide range of different model systems and experimental strategies have been used, the insulin and insulin-like growth factor 1 receptor (IGF1R) signalling pathway, which involves the phosphoinositide 3-kinase (PI3K) and AKT kinases and the Forkhead box protein O (FOXO) transcription factors (such as DAF-16 in Caenorhabditis elegans), has emerged as a key process. The downregulation of HSF reduces the lifespan and accelerates the formation of protein aggregates in C. elegans carrying mutations in different components of the IGF1R-mediated pathway. Conversely, inhibition of IGF1R signalling results in HSF activation and promotes longevity by maintaining proteostasis 110,111 . These results have prompted many laboratories that use other model organisms to investigate the functional relationship between HSFs and the IGF1R signalling pathway.

The impact of HSFs on the lifespan of whole organisms is further emphasized by a recent study, in which proteome stability was examined during C. elegansageing 112 . The age-dependent misfolding and downregulation of distinct metastable proteins, which display temperature-sensitive missense mutations, was examined in different tissues. Widespread failure in proteostasis occurred rapidly at an early stage of adulthood, coinciding with the severely impaired heat shock response and unfolded protein response 112 . The age-dependent collapse of proteostasis could be restored by overexpression of HSF and DAF-16, strengthening the evidence for the unique roles of these stress-responsive transcription factors to prevent global instability of the proteome.

Limited food intake or caloric restriction is another process that is associated with an enhancement of lifespan. In addition to promoting longevity, caloric restriction slows down the progression of age-related diseases such as cancer, cardiovascular diseases and metabolic disorders, stimulates metabolic and motor activities, and increases resistance to environmental stress stimuli 113 . To this end, the dynamic regulation of HSF1 by the NAD + -dependent protein deacetylase SIRT1, a mammalian orthologue of the yeast transcriptional regulator Sir2, which is activated by caloric restriction and stress, is of particular interest. Indeed, SIRT1 directly deacetylates HSF1 and keeps it in a state that is competent for DNA binding. During ageing, the DNA-binding activity of HSF1 and the amount of SIRT1 are reduced. Consequently, a decrease in SIRT1 levels was shown to inhibit HSF1 DNA-binding activity in a cell-based model of ageing and senescence 42 . Furthermore, an age-related decrease in the HSF1 DNA-binding activity is reversed in cells exposed to caloric restriction 114 . These results indicate that HSF1 and SIRT1 function together to protect cells from stress insults, thereby promoting survival and extending lifespan. Impaired proteostasis during ageing may at least partly reflect the compromised HSF1 activity due to lowered SIRT1 expression.

Impact of HSFs in disease

The heat shock response is thought to be initiated by the presence of misfolded and damaged proteins, and is thus a cell-autonomous response. When exposed to heat, cells in culture, unicellular organisms, and cells in a multicellular organism can all trigger a heat shock response autonomously 115–117 . However, it has been proposed that multicellular organisms sense stress differently to isolated cells. For example, the stress response is not properly induced even if damaged proteins are accumulated in neurodegenerative diseases like Huntington’s disease and Parkinson’s disease, suggesting that there is an additional control of the heat shock response at the organismal level 118 . Uncoordinated activation of the heat shock response in cells in a multicellular organism could cause severe disturbances of interactions between cells and tissues. In C. elegans, a pair of thermosensory neurons called AFDs, which sense and respond to temperature, regulate the heat shock response in somatic tissues by controlling HSF activity 119,120 . Moreover, the heat shock response in C. elegans is influenced by the metabolic state of the organism and is reduced under conditions that are unfavourable for growth and reproduction 121 . Neuronal control may therefore allow organisms to coordinate the stress response of individual cells with the varying metabolic requirements in different tissues and developmental stages. These observations are probably relevant to diseases of protein misfolding that are highly tissue-specific despite the often ubiquitous expression of damaged proteins and the heat shock response.

Elevated levels of HSF1 have been detected in several types of human cancer, such as breast cancer and prostate cancer 122,123 . Mice deficient in HSF1 exhibit a lower incidence of tumours and increased survival than their wild-type counterparts in a classical chemical skin carcinogenesis model and in a genetic model expressing an oncogenic mutation of p53. Similar results have been obtained in human cancer cells lines, in which HSF1 was depleted using an RNA interference strategy 124 . HSF1 expression is likely to be crucial for non-oncogene addiction and the stress phenotype of cancer cells, which are attributes given to many cancer cells owing to their high intrinsic level of proteotoxic and oxidative stress, frequent spontaneous DNA damage and aneuploidy 125 . Each of these features may disrupt proteostasis, raising the need for efficient chaperone and proteasome activities. Accordingly, HSF1 would be essential for the survival of cancer cells that experience constant stress and develop non-oncogene addiction.

HSFs as therapeutic targets

Given the unique role of HSF1 in stress biology and proteostasis, enhanced activity of this principal regulator during development and early adulthood is important for the stability of the proteome and the health of the cell. However, HSF1 is a potent modifier of tumorigenesis and, therefore, a potential target for cancer therapeutics 125 . In addition to modulating the expression of HSF1, the various PTMs of HSF1 that regulate its activity should be considered from a clinical perspective. As many human, age-related pathologies are associated with stress and misfolded proteins, several HSF-based therapeutic strategies have been proposed 126 . In many academic and industrial laboratories, small molecule regulators of HSF1 are actively being searched for (see Supplementary information S1 (table)). For example, celastrol, which has antioxidant properties and is a natural compound derived from the Celastreace family of plants, activates HSF1 and induces HSP expression with similar kinetics to heat shock, and could therefore be a potential candidate molecule for treating neurodegenerative diseases 127,128 . In a yeast-based screen, a small-molecule activator of human HSF1 was found and named HSF1A 129 . HSF1A, which is structurally distinct from the other known activators, activates HSF1 and enhances chaperone expression, thereby counteracting protein misfolding and cell death in polyQ-expressing neuronal precursor cells 129 . Triptolide, also from the Celastreace family of plants, is a potent inhibitor of the transactivating capacity of HSF1 and has been shown to have beneficial effects in treatments of pancreatic cancer xenografts 130,131 . These examples of small-molecule regulators of HSF1 are promising candidates for drug discovery and development. However, the existence of multiple mammalian HSFs and their functional interplay should also be taken into consideration when planning future HSF-targeted therapies.

Concluding remarks and future perspectives

HSFs were originally identified as specific heat shock-inducible transcriptional regulators of HSP genes, but now there is unambiguous evidence for a wide variety of HSF target genes that extends beyond the molecular chaperones. The known functions governed by HSFs span from the heat shock response to development, metabolism, lifespan and disease, thereby integrating pathways that were earlier strictly divided into either cellular stress responses or normal physiology.

Although the extensive efforts from many laboratories focusing on HSF biology have provided a richness of understanding of the complex regulatory mechanisms of the HSF family of transcription factors, several key questions remain. For example, what are the initial molecular events (that is, what is the ‘thermometer’) leading to the multistep activation of HSFs? The chromatin-based interaction between HSFs and the basic transcription machinery needs further investigation before the exact interaction partners at the chromatin level can be established. The activation and attenuation mechanisms of HSFs require additional mechanistic insights, and the roles of the multiple signal transduction pathways involved in post-translational regulation of HSFs are only now being discovered and are clearly more complex than anticipated. Although still lacking sufficient evidence, the PTMs probably serve as rheostats to allow distinct forms of HSF-mediated regulation in different tissues during development. Further emphasis should therefore be placed on understanding the PTMs of HSFs during development, ageing and different protein folding diseases. Likewise, the subcellular distribution of HSF molecules, including the mechanism by which HSFs shuttle between the cytoplasm and the nucleus, remains enigmatic, as do the movements of HSF molecules in different nuclear compartments such as NSBs.

Most studies on the impact of HSFs in lifespan and disease have been conducted with model organisms such as D. melanogaster and C. elegans, which express a single HSF. The existence of multiple members of the HSF family in mammals warrants further investigation of their specific and overlapping functions, including their extended repertoire of target genes. The existence of multiple HSFs in higher eukaryotes with different expression patterns suggests that they may have functions that are triggered by distinct stimuli, leading to activation of specific target genes. The impact of the HSF family in the adaptation to diverse biological environments is still poorly understood, and future studies are likely to broaden the prevailing view of HSFs being solely stress-inducible factors. To this end, the crosstalk between distinct HSFs that has only recently been uncovered raises obvious questions about the stoichiometry between the components in different complexes residing in different cellular compartments, and the mechanisms by which the factors interact with each other. Interaction between distinct HSF family members could generate new opportunities in designing therapeutics for protein-folding diseases, metabolic disorders and cancer.

Heat Shock Response and Protein Degradation: Regulation of HSF2 by the Ubiquitin-Proteasome Pathway

Fig. 1 . Activation of HSF2 by treatment of cells with specific proteasome inhibitors. (A) Gel mobility shift assays to analyze formation of HSF-HSE complexes using whole-cell extracts prepared from untreated K562, HeLaS3, and HepG2 cells and MEF (lanes 1, 5, 8, and 10, respectively), from K562 cells treated with hemin for 12 h (lane 2) or with MG132 or lactacystin (Lac) for 2 h (lanes 3 and 4, respectively), from HeLaS3 cells treated with MG132 or lactacystin for 6 h (lanes 6 and 7, respectively), from HepG2 cells treated with MG132 for 2 h (lane 9), and from MEF treated with MG132 for 2 h (lane 11). (B) Identification of the DNA-binding activity as primarily HSF2 by antibody supershift assays. Extracts from hemin- and MG132-treated K562 cells (lanes 1 to 3 and 4 to 6, respectively) were incubated either with or without a 1:50 dilution of specific HSF2 or HSF1 antisera, as indicated, prior to the gel mobility shift assay. Similarly, extracts from MEF heat shocked at 42°C for 1 h (lanes 7 to 9) or treated with MG132 for 6 h (lanes 10 to 13) were incubated in the presence or absence of either the antiserum specific to HSF1, the antiserum specific to HSF2, or both. The HSF DNA-binding activities are indicated by arrows. NS, nonspecific binding.

HSF2 is activated in a cell line expressing a conditional mutation in the ubiquitination pathway.

Fig. 2 . Inhibition of efficient ubiquitination activates HSF2. (A) Gel shift analysis of ts85 cells maintained at control (30°C) (lane 1) and nonpermissive (39.5°C) (lanes 2 to 4) temperatures for the lengths of time shown. (B) Antibody supershift analyses of the sample at 39.5°C for 6 h were performed by incubation of extracts in the absence (lane 1) or presence of antiserum specific for HSF2 (lane 2) or HSF1 (lane 3).

HSF2 is a labile protein which accumulates during proteasome inhibition.

Fig. 3 . Coordinate changes in HSF2 DNA-binding activity and protein levels, determined by gel mobility shift (upper panels) and immunoblot (lower panels) assays of whole-cell extracts from MEF treated with MG132 for up to 6 h (A), ts85 cells incubated at the nonpermissive temperature for up to 4 h in the presence (lanes 4 and 5) or absence (lanes 2 and 3) of cycloheximide (CHX) (B), K562 cells left untreated (lane 1) or treated for 2 h with MG132 alone (lane 2) or with MG132 and cycloheximide (lane 3) (C), and K562 cells left untreated (lane 1) or treated with MG132 for 6 h and allowed to recover for 0 (lane 2), 4 (lane 3), and 10 (lane 4) h in inhibitor-free medium (D). C, control. Fig. 4 . Inhibition of protein synthesis results in a loss of HSF2 DNA-binding activity and of HSF2 protein levels. (A) Gel mobility shift (upper panel) and immunoblot (lower panel) assays of whole-cell extracts from K562 cells left untreated (lane 1) or induced with hemin for 12 h and treated with cycloheximide (CHX) for 0 (lane 2), 30 (lane 3), or 120 (lane 4) min. (B) The effects of simultaneous inclusion of cycloheximide and MG132, for 0 (lane 1), 30 (lane 2), and 120 (lane 3) min, on hemin-induced cells were also assessed. (C) Glycerol gradient fractionation (55) of K562 cell extracts from control cells (I) and from cells induced with hemin for 12 h (II to IV) and treated with cycloheximide for 0 (II), 30 (III), or 120 (IV) min. Fractions were collected from the top to the bottom of the gradients (fractions 2 to 16). The positions corresponding to dimeric and trimeric HSF2 are shown. The S values from protein standards are indicated (cytochrome c, 1.9S bovine serum albumin, 4.3S alcohol dehydrogenase, 7.4S). Fig. 5 . Estimation of HSF2 half-life. Hemin-treated K562 cells were treated with cycloheximide, and samples were taken at various time points up to 4 h of treatment. Cell extracts were prepared, and 10-μg amounts were used for SDS-PAGE and immunoblot analyses. The HSF2 protein visualized by ECL was quantitated by scanning densitometry. Data compiled from 12 experiments (correlation coefficients, >0.995) are shown. The half-life of HSF2 is calculated to be 60 min from a logarithmic plot of percentages of original HSF2 protein versus time (in minutes). Fig. 6 . Elevated synthesis and decreased degradation of HSF2 upon proteasome inhibition. (A) Control MEF (lane 1) and MEF treated with MG132 for 2 (lane 2) and 6 (lane 3) h were pulse-labeled for 15 min, following which cell extracts were prepared for use for immunoprecipitation (upper panel) and immunoblot (lower panel) analyses as described above. The labeled proteins were visualized by fluorography and quantitated by PhosphorImager analysis. The labeled protein band appearing above 208 kDa represents a nonspecific interaction with the antibodies. (B) MEF treated with MG132 for 4 h were pulse-labeled for 15 min and incubated in complete medium with (lane 3) or without (lane 2) MG132 for an additional 4 h. Cell extracts were prepared and used for immunoprecipitation analyses as described above.

Inhibition of proteasome activity results in induction of heat shock gene expression.

Fig. 7 . Induction of heat shock proteins in K562 cells by proteasome inhibitor treatment. (A) 35 S-labeled cell extracts from pulse-labeled cells analyzed by SDS–10% PAGE. Cells were left untreated (lane 1), treated with 10 μM MG132 for 2 or 6 h (lanes 2 and 3), treated with 10 μM lactacystin (Lac) for 2 or 6 h (lanes 4 and 5), or heat shocked (HS) at 42°C for 1 h (lane 6). (B) Hsp70 immunoblot of cell extracts using the mouse monoclonal antibody 4G4. From left to right, treatments correspond to those described for panel A, lanes 1 through 6. (C) Hdj-1 immunoblot of cell extracts using rabbit polyclonal sera raised against Hdj-1. From left to right, treatments correspond to those described for panel A, lanes 1 through 6. (D through F) Two-dimensional protein gel analysis of 35 S-labeled cell extracts left untreated (D), treated with 10 μM MG132 for 6 h (E), or heat shocked at 42°C for 1 h (F). The first dimension was isoelectric focusing generating a gradient from pH 3 to 10. The second dimension was SDS–10% PAGE. Open arrowhead, location of Hsc70 solid arrowhead, location of Hsp70 arrow, location of Hsp90. The circled proteins of approximately 35 kDa are induced preferentially upon MG132 treatment. The protein spot labeled a corresponds to actin.


The challenge to the cell and organism in the face of acute and chronic proteotoxic stress associated with aging, stress, and disease is a system-wide decline in proteostasis and cellular function. The consequence of proteome mismanagement is substantial as evident by the large and growing number of diseases of protein conformation. Protein aggregation, however, is not an isolated event and, once imbalanced, causes an acceleration in the levels of damaged proteins, leading to a rapid decline in biosynthetic and repair activities and multiple cell stress responses, which over time have deleterious consequences on the health and aging of the organism.

Watch the video: Chaperone Heat Shock Protein 70 Mechanism! (December 2021).